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ABSTRACT 
The psrt mutations, 723SJ and 1060SJ, are END-induced, non-complementing 
mutations that produce identical phenotypes and map to the same p-deletion interval on 
mouse chromosome 7. psrt stand for profound seizure and runting; animals exhibiting 
this phenotype are runted and have severe seizures that are first detected at seven to ten 
days of age. Homozygous and hemizygous mutants typically live 15 to 18 days. A 
positional cloning strategy was employed to identify the gene responsible for this 
phenotype. The region of the genome containing psrt was better defined by mapping 
molecular markers and determining the breakpoints of p3RD3ooH, a p-deletion that does 
not complement the phenotype. A physical map was constructed in the minimal 
deletion interval determined to contain the mutation, and a Bacterial Artificial 
Chromosome from the physical map was sequenced to identify candidate genes. Three 
genes were identified, two from sequence analysis (Tat-interacting protein (30 kDa), 
Tip30, and protein arginine N-methyltransferase 3, Prmt3) and one from a search of the 
genome sequencing databases from the human region of homology (glycine transporter 
type 2, GLYT2). No mutations were detected in the Tip30 cDNA and G/yt2 was not 
molecularly characterized. However, the 5' end of the 723SJ Prmt3 transcript could not 
be amplified, indicating a possible chromosomal rearrangement or deletion, and 
mutation screening by temperature-gradient capillary electrophoresis was utilized to 
detect mismatches between the control and both the 723SJ and 1060SJ cDNAs. This 
indicates that mutations in the Prmt3 transcript are present in both strains of mutants. 
lV 
Initial sequence analysis failed to detect a mutation; however, further sequencing will 
be performed to verify the mismatches. Since Prmt3 could be involved in the 
methylation of the single methylarginine residue in the myelin basic protein, an assay to 
detect the presence of this residue in the myelin basic protein hydrolysate was 
performed on mutants and controls from the 1060SJ strain of mice. Results indicate 
that the methylarginine is easily detected in the 1060SJ control animals, but could not 
be detected in the 1060SJ psrt mutants. The molecular and biochemical evidence 
suggests that Prmt3 is the gene responsible for the psrt phenotype. 
V 
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OVERVIEW OF THE PROJECT ~TI DESCRIPTION OF THE psrt PHENOTYPE 
OVERVIEW 
This dissertation documents the positional cloning of the gene responsible for 
the profound seizure and runting (psrt) phenotype on mouse chromosome 7. Chapter 
one contains an overview of the project and a description of the phenotype. Chapter two 
contains the background information on the genetic reagents utilized in this project as 
well as the methodology utilized to produce the mutants. Chapter three contains a 
summary of the trans-complementation data that allowed the mutation to be fine-
mapped. Chapters four, five, seven and eight contain experimental data and include 
five major sections: abstract, introduction, materials and methods, results, and 
discussion. Chapter four covers physical mapping in the psrt region, chapter five 
covers the sequence analysis of genomic clones in the region, chapter seven covers an 
expression analysis of candidate genes and a sequence analysis of their transcripts, and 
chapter eight covers the analysis of methylarginine in the myelin basic protein of 
mutant and control animals. Chapter six consists of a detailed literature review of the 
candidate genes and Chapter nine is an evaluation of the candidates. Chapter ten, the 
final chapter, is a brief assessment of future work that is needed to give closure to the 
project. Literature references and an appendix containing the tables, figures and 
legends follow the ten chapters. 
1 
THE psrt PHENOTYPE 
This project undertook the positional cloning of the gene responsible for a 
juvenile lethal, neurological phenotype called psrt, for "profound seizure and runting." 
As the name implies, this phenotype manifests as severe seizures and runting. The 
seizures, characterized by stiffened and extended limbs, are first detected in the mutants 
at around seven to ten days after birth. Seizure activity increases in intensity and 
duration until the animal eventually dies, at around 15-18 days. Mutants can easily be 
distinguished from their non-mutant littermates by their runted appearance, even at 
birth. Their development appears to be delayed, since not only are they smaller in size, 
but also their fur is sparse and slow to come in. This runtedness is not due to starvation 
because milk is visible in the pups' stomachs, even after the onset of seizure activity 





This research was performed using mutant animals generated over the years in 
the mutagenesis programs at the Oak Ridge National Laboratory (ORNL). What 
follows is a brief overview of the development of the genetic and molecular reagents 
utilized in these mutagenesis studies as well as a description of the mutagenesis 
programs themselves. 
THE SPECIFIC LOCUS TEST (SLT) 
The morphological specific locus test (SLT) was developed in the late 1940s by 
William L. (Bill) Russell at the ORNL to investigate the induction of heritable 
mutations in the mammalian germline by ionizing radiation (Russell, 1951 ). To enable 
the recovery of new recessive mutations, Russell constructed the mouse T (tester) stock, 
which is homozygous for then-existing recessive alleles at seven loci that code for 
visible phenotypes in the mouse. The seven loci, located on five chromosomes, include 
six that affect coat color and one that affects ear morphology. The recessive T-stock 
alleles at three unlinked loci are: non-agouti (a) at the a locus on chromosome 2; brown 
(b; Tyrplb) at the tyrosine-related protein (Tyrpl) locus on chromosome 4; and piebald 
spotting (s; Ednrb 5) at the endothelin receptor type B (Ednrb) locus on chromosome 14. 
Alleles at two sets of linked loci are: pink-eyed dilution (p) at the p locus and chinchilla 
3 
(cc\ Tyre-ch) at the Tyrosinase (Tyr) locus, 15 centimorgans (cM) apart on chromosome 
7; and dilute (d; Myo5ad) at the myosin SA (Myo5a) locus and short-ear (se; Bmp5se) at 
the bone morphogenetic protein 5 (Bmp5) locus, 0.16 cM apart on chromosome 9 
(Russell, 1951 ). 
The SL T is performed by exposing mice that are homozygous wild type at all 
seven specific loci to a potential mutagen, then mating them to T-stock animals. If no 
new mutations are induced at any of the seven loci, all offspring of this mating are 
phenotypically wild type; however, if one or more recessive mutations were generated 
at any of the seven loci, mutant animals would be detected in the first-generation of 
offspring. Dominant visible mutations induced anywhere in the genome are detectable. 
If a newly induced mutation at one of the specific loci is lethal, this new mutation can 
still be recovered in lines derived from the heterozygous primary F1 mutant by 
appropriate breeding, and can be perpetuated in a stock. The beauty of the SLT is 
threefold: since the loci affect coat color and ear morphology, the mutants are easily, 
quickly, and objectively recognized and categorized by their physical appearance; the 
mutations can be detected in only one generation; and all mutations, including any that 
are recessive lethals, can be recovered and perpetuated (Russell, 1951). 
The SLT was initially used at the Oak Ridge National Laboratory to ascertain 
the rate of induction of heritable mutations by ionizing radiations in mouse germ cells, 
and, specifically, the effects of various physical and biological variables on the 
frequency and nature of the induced mutations. This information was desperately 
needed, since the effects of ionizing radiation on the human germ line were unknown at 
4 
the time. The only other organisms in which radiation-mutagenesis studies had been 
performed at that time were maize, Zea mais, and the fruit fly, Drosophila 
melanogaster; however, Russell felt that data from mammalian species were necessary 
because they would more closely estimate the effect on humans. He designed the SLT 
primarily to give quantitative data by measuring the mutation rate at each of the seven 
loci. However, he also designed the SLT to give qualitative information about the 
mutations emerging from the studies, since two of the loci are very tightly linked (d and 
se are a mere 0.16 cM apart on chromosome 9) and a point mutation or intragenic lesion 
would affect only one of the two loci while a deletion might affect both loci (Russell, 
1951 ). 
Because the SLT measured mutation rates at each of the specific loci, Russell 
was able to conclude early in his work that genes vary greatly in their mutability 
(Russell, 1951 ). Bill and Liane B. (Lee) Russell determined that chronic doses of 
radiation produced fewer detectable mutations in spermatogonial stem cells (Russell et 
al., 1958) and in oocytes (reviewed in Russell and Russell, 1992) than the same amount 
of radiation administered in a single, acute dose, providing early evidence for repair of 
premutational damage (Russell et al., 1958). They also used the SLT to study the 
genetic effects of numerous chemical mutagens. These experiments revealed that the 
stage at which germ-cells were exposed had a profound effect not only on the frequency 
but on the nature of the induced mutations (reviewed in Russell et al. 1990, Russell, 
2001). One of the chemicals investigated, N-ethyl-N-nitrosourea (ENU), was found to 
be by far the most effective mutagen identified in the mouse (Russell et al., 1979b; 
5 
Russell et al., 1981 ). Their work revealed that with ENU, as with radiation, there are 
DNA repair mechanisms active in mouse germ cells (Russell et al., 1982b; Russell et 
al., 1982c). 
An SL T utilizing a different test stock was conducted by a Medical Research 
Council group at Harwell, England. This test stock carried homozygous recessives at 
six specific loci, namely: fuzzy (ft) and leaden (In) on chromosome 1; brachypody (bp; 
growth differentiation factor 5, Gdf5), nonagouti (a), and pallid (pa; Pallidin, Pldn) on 
chromosome 2; and pearl (pe; beta-3A adaptin, Ap3bl) on chromosome 13. Because of 
the selection of a different set of specific loci from those in the Russell T stock, the 
Harwell data indicated a slightly different average mutation rate from that calculated by 
the Russells (Lyon and Morris, 1966). However, their conclusions were identical to 
those drawn from the work at Oak Ridge: ionizing radiation induces heritable 
mutations in mammals at a higher rate than it does in Drosophila melanogaster 
(Russell, 1951; Lyon and Morris, 1966). 
DELETION COMPLEXES IN THE MOUSE GENOME 
The radiation mutagenesis work at ORNL led to the isolation of numerous 
mutations at the seven specific loci. Molecular and genetic analyses of mice carrying 
these mutations led to the conclusion that many of the mutations are chromosomal 
deletions of varying sizes. Crosses between pairs of mutants at each locus, followed by 
a detailed phenotypic analysis of the progeny of these crosses, led to the identification 
of complementation groups. Subsequent molecular analysis within complementation 
6 
groups has allowed each family of deletions to be ordered into a deletion complex, 
consisting of a set of nested and overlapping deletions (reviewed in Russell and 
Rinchik, 1987 and Russell, 1989; O'Brien et al., 1996). In addition to those generated 
at ORNL, deletion complexes have been produced by other groups at some of the same 
(i.e. the pink-eyed dilution) and other loci. These mutations have been induced through 
mutagenesis schemes utilizing either ionizing radiation in mice (Lyon and Morris, 
1966) or embryonic stem (ES) cells (You et al., 1997; Thomas et al. 1998; Schimenti et 
al., 2000), or Cre-LoxP recombination in ES cells (Ramirez-Solis et al., 1995). 
Deletion complexes have proven to be an invaluable reagent in the genetic and 
molecular analysis of the regions of the genome that they cover. Crosses between 
carriers of different deletions within the same complex are used to identify regions of 
the genome ( called complementation groups) that are associated with a particular 
phenotype by examining the offspring of such crosses to determine what "functions" are 
missing. The missing "function(s)" must map to the region of the genome deleted by 
the overlap of the two deletions (Rinchik and Russell, 1987; Rinchik and Russell, 
1990). Such genetic, or complementation, analyses have been used to identify 
complementation groups in the brown (b) region of chromosome 4 (Rinchik, 1994), the 
albino (c) region of chromosome 7 (Gluecksohn-Waelsch, 1979; Russell et al., 1982a; 
Russell et al., 1979a; Niswander et al., 1988; Russell, 1979; Russell and Raymer, 1979, 
Rinchik and Carpenter, 1999), the pink-eyed dilution (p) region of chromosome 7 (Lyon 
et al., 1992; Russell et al., 1995), the dilute-short ear (d-se) region of chromosome 9 
(Russell, 1971), and the piebald (s) region of chromosome 14 (O'Brien et al., 1996). 
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Perhaps the most valuable use of the deletion complexes is as a reagent for fine-
structural mapping by crossing an animal that is either homozygous ( carrying two 
copies of a single allele) or heterozygous (containing two different alleles) for the 
recessive trait to be mapped to animals carrying chromosomal deletions from the 
genomic region of interest. If the recessive phenotype maps within the deletion being 
tested, then the hemizygous offspring ( containing a single allele opposite a deletion) 
exhibit the recessive phenotype. If the recessive phenotype does not map within the 
deletion being tested, then the offspring are heterozygous and exhibit a wild-type 
phenotype (reviewed m Rinchik and Russell, 1990). These types of trans-
complementation crosses have been used extensively to map numerous recessive 
phenotypes and genes to various deletions, including the albino (c) deletion complex on 
chromosome 7 (Russell et al., 1982a; Rinchik et al., 1993b; Potter and Rinchik, 1993; 
Potter et al., 1995; Rinchik and Carpenter, 1993 and 1999), the p deletion complex on 
chromosome 7 (Culiat et al., 1993), the Krd deletion on chromosome 19 (Ji et al., 
1999), and the Brachyury (1) deletion complex on chromosome 17 (Bergstrom et al., 
1998). 
The deletion complexes can also be used to fine-map molecular markers and 
probes relative to the deletion breakpoints. This is accomplished through the use of 
panels of DNAs from F 1 hybrids of an interspecific cross, e.g. Mus musculus X Mus 
spretus cross, with the chromosomal deletion of interest carried on the Mus musculus 
chromosome. Taking advantage of the high rate of polymorphism between the Mus 
musculus and related Mus species (Silver, 1995), any molecular probe showing a 
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restriction fragment length polymorphism (RFLP) between two species can be used for 
mapping. If the probe maps within the deletion being tested, then the hybridization 
band corresponding to the Mus spretus allele, e.g., will be present and the band 
corresponding to Mus musculus (which carries the deletion) will be absent. On the 
other hand, if the probe maps outside the deletion, then both the Mus spretus and the 
Mus musculus bands will be present. The band corresponding to the Mus spretus allele 
will always be present; therefore, the presence or absence of the Mus musculus band 
indicates whether or not the probe is deleted (reviewed in Russell and Rinchik, 1987). 
Similarly, any PCR amplification product that shows a polymorphism between Mus 
musculus and Mus spretus can also be used for mapping, with the presence or absence 
of the Mus musculus product determining whether or not the product maps within the 
deletion (Metallinos et al., 1994). Fine-structure mapping has been utilized to 
molecularly characterize the genomic regions surrounding several of the deletion 
complexes, including the albino (c) deletion complex on chromosome 7 (Johnson et al., 
1989; Rinchik et al., 1989; Holdener et al., 1995; Rikke et al., 1997), the p deletion 
complex on chromosome 7 (Johnson et al., 1995; Dhar and Johnson, 1997; Culiat et al., 
1993; Culiat et al., 1994; Nicholls et al., 1993; Scrable et al., 1990; Stubbs et al., 1994; 
Walkowicz et al., 1999; Wu et al., 2000), the brown (b) deletion complex on 
chromosome 4 (Rinchik et al., 1994; Bell et al., 1995), the piebald (s) deletion complex 
on chromosome 14 (Metallinos et al., 1994; O'Brien et al., 1996), the Brachyury (7) 
deletion complex on chromosome 17 (You et al., 1997), and the interdigitated 
Huntington disease (Hdh ), dipeptydylpeptidase VI (Dpp6), and y-aminobutyric acid 
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receptor, P-1 subunit (Gabrbl) deletion complexes on chromosome 5 (Schimenti et al., 
2000). 
One advantage of using the deletion complexes for mapping, both genetic and 
molecular, is that the resolution is much higher than that typically obtained using 
traditional recombination mapping techniques (Rinchik and Russell, 1990; Bergstrom et 
al., 1998; Schimenti et al., 2000). In addition, any probe or amplification product that 
is polymorphic can be mapped relative to the deletion breakpoints. This means that 
entire genomic or cDNA clones, as well as anonymous clones and PCR products, can be 
mapped, even if their genetic or biochemical function is unknown. The maps produced 
by these types of analyses are dynamic; they continually evolve as the genes and 
functional units in these regions become better understood. 
Another important use of the deletion complexes and other chromosomal 
rearrangements is in regional mutagenesis studies (Rinchik et al., 1990). In fact, 
deletions have been called the "critical genetic reagent" (Schimenti and Bucan, 1998) 
that, along with the supermutagen ENU, has fueled the explosion of regional 
mutagenesis experiments in the mouse in progress worldwide (Justice et al., 1999). By 
mutagenizing a region of the genome corresponding to any of the deletion complexes, it 
is possible to identify mutations through a hemizygous, two-generation breeding 
scheme, rather than the three-generation screen that would be required to identify them 
homozygously. Furthermore, any recessive mutations detected in the hemizygous 
breeding scheme presumed to map within the genomic location defined by the extent of 
the deletion can be quickly fine-mapped using trans-complementation crosses to 
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deletion carriers (Rinchik and Russell, 1990; Rinchik, 1991; Schimenti and Bucan, 
1998; Schimenti et al., 2000). 
Deletion complexes have also been utilized in other ways. For instance, the Krd 
deletion has been used as a reagent in a sensitized screen for genes affecting kidney and 
retinal function. This is possible because the paired box gene 2 (Pax2) maps within the 
Krd deletion, and haploinsufficiency of Pax2 causes kidney and retinal abnormalities (Ji 
et al., 1999). The deletion complexes have also be used to determine the biological 
effect(s) of segmental haploidy on the specific regions of the genome covered by these 
complexes (Schimenti et al., 2000). Mice carrying chromosomal deletions in the p-
deletion complex of mouse chromosome 7 (Mmu7) have been used to study an obesity 
phenotype that appears to be imprinted (Dhar et al., 2000), and mice carrying other 
deletions are being used to dissect contiguous gene syndromes such as Wolf-Hirshhorn 
syndrome (Schimenti et al., 2000) and Di George syndrome (Lindsay et al., 1999). 
Deletions and deletion complexes produced in the mouse are reagents of 
unparalleled importance to mouse geneticists. The genetic and molecular analysis of 
genomic regions corresponding to these deletions and deletion complexes has produced 
a constantly evolving, high-resolution map of these regions. Recessive phenotypes and 
mutations, as well as cDNA and genomic clones and other molecular probes and 
markers (even anonymous markers), can be mapped relative to the deletion breakpoints 
within the complex to produce a higher resolution map than can be produced through 
traditional linkage analysis. Deletions and deletion complexes can be used to study 
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genomic imprinting, to dissect the phenotypes associated with contiguous gene 
syndromes, and as a genetic reagent in regional mutagenesis programs. 
THE pink-eyed dilution (p) LOCUS 
The pink-eyed dilution (p) locus of the mouse is an historically important region 
of the mouse genome. The first report of genetic linkage in mammals was between p 
and the albino (c), or tyrosinase (tyr) locus in the mouse (Haldane et al., 1915). In 
addition, p is one of the seven genetic loci selected for use in the mouse SL T (Russell, 
1951). 
There have been over 100 mutations identified and reported at the p locus of 
mouse chromosome 7 (Lyon et al., 1992; Brilliant et al., 1994; Johnson et al., 1995). 
At least 45 of these p mutations are classified as chromosomal deletions of varying 
sizes, and most of these deletions are homozygous-lethal (Russell et al., 1995). In the 
mouse, the original p mutation, which is a recessive and hypomorphic allele (Rinchik et 
al., 1993a), is of Mus musculus (Asian) origin, while the wild-type (P) allele is of Mus 
domesticus origin (Brilliant et al., 1994). Mutations at the p locus are associated with 
reduced pigmentation of both the eyes and skin, with a reduction in the quantity of 
eumelanin (black-brown pigment) produced by the melanosomes as well as an 
alteration of the size and shape of the melanosomes (Russell, 1949). The protein 
encoded by the P gene is hydrophobic, with 12 putative transmembrane domains 
(Rinchik et al., 1993a). It has a mass of 110 kDa and is localized to the membrane of 
the melanosome (Rosemblat et al., 1994). 
12 
In humans, the P locus maps to chromosome 15ql l.2-q12, and mutations at or 
near this locus have been associated with several diseases, including Prader-Willi and 
Angelman Syndromes and hypomelanosis of Ito (Gardner et al., 1992; Brilliant, 1992). 
Mutations in the human P gene itself have been shown to cause tyrosinase-positive 
oculocutaneous albinism type II (OCA2) (Ramsay et al., 1992; Rinchik et al., 1993a; 
Lee et al., 1994). The human P protein contains 25 exons (the first of which is non-
coding) and covers a genomic interval of between 250- and 600-kb. The protein is 838 
amino acids long and, like the mouse protein, contains 12 putative transmembrane 
domains and is localized to the melanosome membrane. The protein shows homology 
to several prokaryotic transport proteins, including those from species such as 
Escherichia coli, Staphylococcus aureus, and Mycobacterium leprae (Lee et al., 1995). 
Therefore, although the exact function of the P protein has not been demonstrated, it is 
hypothesized that this protein is likely involved in the transport of tyrosine or some 
intermediate in the tyrosine metabolic pathway (Rinchik et al., 1993a). 
THE pink-eyed dilution (p) DELETION COMPLEX 
The pink-eyed dilution (p) deletion complex consists of a series of nested, 
overlapping chromosomal deletions produced by the radiation mutagenesis programs at 
the Oak Ridge National Laboratory and at the M.R.C. Radiobiology Unit at Harwell, 
England. The physical distance covered by the p-deletion complex is unknown; 
however, it must span at least 6.6 cM of genetic distance, since p and Myodl are 5.5 cM 
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apart and Gabrb3 and D7Cwr 15 are 1.1 cM apart, and all are contiguous within the 
complex (Johnson et al., 1995) (Figure II-1, in the Appendix). 
The p-deletion complex has been grossly molecularly characterized, and the 
current genetic and physical map of the region includes gene loci, microsatellite 
markers, and functional units (such as ruby-eye 2; ru2) (Russell, 1989; Johnson et al., 
1995; Stubbs et al., 1994; Dhar and Johnson, 1997; Wu et al., 2000; Scrable et al., 
1990; Walkowicz et al., 1999; Nicholls et al., 1993; Culiat et al., 1993; Culiat et al., 
1994). The proximal (nearest the centromere) region of the complex is homologous to 
human chromosome llp14-p15 (Scrable et al., 1990; DeBry and Seldin, 1996), while 
the distal (nearest the telomere) region of the complex, including P itself, is 
homologous to human chromosome 15qll-q13 (Nicholls et al., 1993; DeBry and 
Seldin, 1996). The p-deletion complex covers a genomic interval that spans from 
lactate dehydrogenase-C (Ldh3), serum amyloid Al (saal) and myogenic 
differentiation antigen 1 (Myodl) at the proximal end of the complex to y-aminobutyric 
acid receptor, P-3 subunit ( Gabrb3) and human papilloma virus E6-associated protein 
(Hpve6a), later renamed ubiquitin-protein ligase E3a (Ube3a), at the distal end of the 
complex (Russell and Rinchik, 1987; Scrable et al., 1990; Johnson et al., 1995). The 
limits of the complex are defined by the proximal breakpoint of the most proximally 
extending deletion, p 46DFioD, and the distal breakpoint of the most distally extending 
deletion, p 30PUb (Russell, 1989; Johnson et al., 1995) (Figure II-I). 
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N-ethyl-N-nitrosourea (ENU) 
N-ethyl-N-nitrosourea (ENU) is the most effective mutagen identified in the 
mouse, with a mutation rate 87 times higher than the spontaneous mutation rate and 
over ten times the maximum mutation rate of a single dose of x-rays (Russell et al., 
1979b; Hitotsumachi et al., 1985). It is an alkylating agent that is both a toxin and a 
carcinogen (reviewed in Justice et al., 2000). It can induce mutations in somatic and 
germ cells in a variety of organisms; therefore, it can be used to induce somatic tumors 
as well as germline mutations (Davis et al., 1999). ENU causes the highest mutation 
rate in stem cell spermatogonia; however, it has been shown to cause mutations in 
mature and maturing oocytes and post-spermatogonial stem cells at a lower rate 
(Russell and Russell, 1992; Russell et al., 1979b ). ENU is widely used in mutagenesis 
experiments because of its high efficiency and its pronounced effects in spermatogonial 
stem cells; mutagenized males can produce large numbers of offspring carrying these 
mutations throughout their reproductive lifetime (Rinchik, 1991; Schimenti and Bucan, 
1998). 
ENU alkylates DNA through an SN1 (unimolecular nucleophilic substitution) 
reaction mechanism in which the ethyl group of ENU is transferred to one of several 
nucleophilic oxygen or nitrogen atoms in any of the four bases of DNA. The sterically 
altered ( ethylated) base causes mispairing during DNA replication, resulting in a point 
mutation in subsequent generations (reviewed in Noveroske et al., 2000). A 
compilation of sequence data from 62 END-induced alleles representing 24 genomic 
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loci indicate that ENU modifies NT base pairs most frequently, with 82% of mutations 
falling into this category (Justice et al., 1999). 
The mutational spectrum of ENU analyzed to date includes missense mutations, 
nonsense mutations, and splicing errors. These mutations can be translated into 
hypomorphic, antimorphic, hypermorphic, and amorphic proteins (Noveroske et al., 
2000). ENU mutagenesis studies have produced multiple alleles at several loci, 
including short ear (Bmp5) (Marker et al., 1997), myosin-VA (MyoVa) (Huang et al., 
1998a; Huang et al., 1998b), Juvenile development and fertility-2 (jdf2/Herc2) 
(Walkowicz et al., 1999), and quaking (qk) (Cox et al., 1999). These allelic series are 
invaluable reagents in the effort to elucidate the in vivo function of genes in a 
mammalian system (Ji et al., 1999; Schimenti et al., 2000), enabling the determination 
of structure-functional relationships in proteins caused by any number of point 
mutations, and allowing the dissection of the biochemical pathways in which these 
genes function. 
In mouse spermatogonia, there is a threshold level below which ENU shows no 
mutagenic effect, indicating that there are cellular mechanisms in place that can repair 
the DNA damage done by ENU, provided that the damage is not too severe (Russell et 
al., 1982b ). Therefore, fractionating a moderate dosage of ENU leads to a lower 
mutation rate (Russell et al., 1982c). Conversely, it has been shown that weekly, 
repeated doses of ENU increase the mutation rate and allow the animals to survive a 
higher dosage that would, if administered in a single dose, be lethal (Hitotsumachi et 
al., 1985). It has also been found that the effects of ENU can vary in the mouse from 
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strain to strain; therefore, genetic background has an effect on ENU susceptibility 
(Davis et al., 1999; Justice et al., 2000). 
ENU is a potent point mutagen that primarily alters A/T base pairs in DNA. It is 
currently the most effective mutagen tested in the mammalian germline, and its effects 
are most pronounced in mouse spermatogonial stem cells. One of the greatest 
advantages of ENU is its ability to produce an allelic series at the locus of interest. Its 
high mutation efficiency, coupled with its ability to produce allelic series, make ENU 
the mutagen of choice for most mutagenesis experiments. 
REGIONAL MUTAGENESIS 
There are several regions of the mouse genome where deletions have been 
utilized as genetic reagents for regional mutagenesis studies. These studies involve 
using ENU to mutagenize a region of the genome that is covered by a deletion, to 
effectively "saturate" the genomic region with point mutations induced by ENU and 
recover these mutations hemizygously using long deletions (reviewed in Rinchik and 
Russell, 1990). It has been suggested that a true "saturation mutagenesis" is probably 
not possible, however, due to the variable mutability of different genetic loci (Rinchik 
and Carpenter, 1999). The advantages to this method are numerous. ENU is the most 
potent mutagen in mouse spermatogonial cells, so it is ideal for mutagenizing male mice 
with high efficiency. It produces primarily point mutations, so many different 
mutations are possible for each gene; therefore, it is possible to produce allelic series, 
which are useful in determining the functions of the genes within the context of the 
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animal. Finally, the use of deletions allows the mutations to be recovered hemizygously 
in only two generations, rather than the three generations that would be required to 
recover them homozygously (Rinchik, 1991). 
REGIONAL MUTAGENESIS EFFORTS AT ORNL 
There have been three major regional mutagenesis projects performed at ORNL. 
In each case, the mutagenesis projects involve the use of ENU as the mutagen and 
deletions produced from the radiation mutagenesis experiments at ORNL to recover the 
mutations in hemizygotes. Since the deletions are opposite an easily identifiable 
morphological marker, the test and carrier classes are conveniently "marked" by their 
morphological features, such as coat and eye color (Rinchik, 2000). The ORNL 
mutagenesis efforts have utilized five deletions at three loci: one deletion from the 
albino (c; Tyr) deletion complex (Rinchik et al., 1990; Rinchik and Carpenter, 1993 and 
1999; Rinchik et al., 1993b), two deletions from the brown (b; Tyrpl) deletion complex 
(Rinchik, 2000; Dabney Johnson, personal communication), and two deletions from the 
pink-eyed dilution (p) deletion complex (Rinchik et al., 1995; Rinchik, 2000). 
REGIONAL MUTAGENESIS WORK IN THE p-DELETION COMPLEX 
The ORNL mutagenesis work in the p-deletion complex has used two different 
deletions, p 46DFiOD and p3°PUb. Although these deletions are overlapping and both delete 
the p gene, the proximal breakpoint of p46DFiOD and the distal breakpoint of p 30PUb define 
the proximal and distal limits, respectively, of the p-deletion complex (Figure II-1). 
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Both of these deletions are homozygous-lethal (Russell et al., 1995), and the p46DFiOD 
deletion, which is cytologenetically visible (Rinchik and Russell, 1990), deletes both p 
and ru2, another coat and eye color mutation located approximately 3 cM proximal top 
(Russell, 1989). The p3°PUb deletion deletes p and the y3, a 5, and p3 subunits of the y-
aminobutyric acid receptor (Gabrg3, Gabra5, and Gabrb3) as well as the ubiquitin-
protein ligase E3a (Ube3a) (Johnson et al., 1995). 
MUTAGENESIS USING THEp 46DFiOD DELETION 
The mutagenesis protocol utilized for this project involves the p 46DFiOD deletion, 
which has two morphological markers, p and ru2. The mutagenized males are 
homozygous ru2 p I ru2 p; therefore, the mutagenized chromosome carries the both the 
original p mutation and ru2, another recessive mutation that produces deep ruby-colored 
eyes and a somewhat diluted gray-brown coat (Silvers, 1979). These males are then 
crossed to females that are homozygous wild-type ( +/+) to produce wild-type G1 
offspring (unless a dominant mutation is induced). The G1 offspring are then mated to 
animals that carry the p 46DFiOD deletion (represented by~) opposite ru2. This cross can 
produce three classes of animals: pink-eyed, ru2 animals (ru2 p I~), which would be 
the test class; ru2 animals (ru2 p I ru2 +, with + representing the wild-type allele, P), 
which are the carrier class; and wild-type ( either ru2 + I + + or + + I ~). Induced 
recessive mutations are detected in the pink-eyed, ru2 test class of animals, and 
deleterious or lethal mutations are recoverable in the ru2 carrier class of animals 
(Rinchik, et al., 1995) (Figure II-2). 
19 
CHAPTER ill 
MAPPING THE psrt PHENOTYPE 
There are two stocks of psrt animals at ORNL, 723SJ and 1060SJ, 
independently generated in the p-region mutagenesis program. These mutations map 
between the p and ru2 loci on Mmu 7 (Figure lli-1). They exhibit identical phenotypes, 
which were originally called "small nervous," and they are non-complementing. Trans-
complementation data indicate that both of these mutations map to the same p-deletion 
interval (E. Rinchik and D. Carpenter, unpublished data), suggesting that these 
mutations are allelic. 
Trans-complementation data show that only four of the p-deletions do not 
complement these two psrt phenotypes: p 46DFioD, p 47Dm, p 3RD3ooH, and p 2MNURJ_ All 
other p-deletions tested complement the phenotype (E. Rinchik and D. Carpenter, 
unpublished data), thereby narrowing down the minimal genomic region known to 
contain the mutant phenotype to a region of Mmu 7 bordered proximally by the 
proximal breakpoint of p 2MNURJ and bordered distally by the proximal breakpoints of 
p 8°K and p 8R250M, which cannot be resolved at this time (Figure lli-1 ). The p3RD 3ooH 
deletion does not complement the psrt phenotype; however, at the beginning of this 
project, its breakpoints had not been well defined and were better characterized in the 
course of this study. 
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CHAPTER IV 
PHYSICAL MAPPING IN THE psrt REGION OF MOUSE CHROMOSOME 7 
ABSTRACT 
A physical map was produced in order to positionally clone the gene responsible 
for psrt, a profound seizure and runting phenotype that maps into the p-deletion 
complex of Mmu 7. The minimal genomic region determined to contain psrt has been 
further defined by molecularly mapping the breakpoints of the p 3RDJOOH deletion. Two 
bacterial artificial chromosome (BAC) libraries were screened using molecular markers 
from the region, and the BACs identified in the screen were further characterized to 
determine their size and to generate sequence tagged sites {STSs) from their terminal, as 
well as internal, sequences. BAC STSs and other molecular markers were mapped 
using deletion panel blots and Southern blots of restriction digested BAC DNAs, and 
data produced were used to assemble and order the physical map. A physical map of a 
portion of the psrt minimal genomic region has been produced, and BAC clones from 
this map were utilized (see Chapter V) to identify transcriptional units in an attempt to 
identify the gene responsible for the psrt phenotype. 
INTRODUCTION 
1. Positional Cloning 
This project used positional cloning to identify the gene responsible for the psrt 
phenotype in the mouse. Positional cloning is a technique that was first utilized in the 
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1980s to clone the human gene responsible for chronic granulomatous disease (Royer-
Pokora et al., 1986). Since that time, positional cloning has been used to clone a 
number of genes in a variety of organisms, including the human genes responsible for 
Duchenne muscular dystrophy, cystic fibrosis, type 1 neurofibromatosis, fragile X 
syndrome, and numerous other diseases (Collins, 1992; Talbot and Schier, 1999; 
Boehm, 1998). The aim of positional cloning is to isolate and clone a gene based solely 
on its chromosomal position in the absence of information about the nature of function 
of either the gene or its protein product (Collins, 1992). 
Positional cloning projects have three basic steps: identifying and mapping 
linked markers, constructing a physical map of the genomic interval determined to 
contain the gene, and searching for genes within this region (Stubbs, 1992; Collins, 
1992). In the first step, identifying and mapping linked markers, pedigrees in which the 
gene of interest is segregating are collected and analyzed (Collins, 1992). This can be 
done either in humans or in model organisms, such as the mouse, and entails analyzing 
polymorphic markers from the region to determine evidence of linkage between the 
mutant phenotype and any of these markers (Collins, 1992; Boehm, 1998). By 
determining which markers are genetically linked to the mutation, it is possible to 
establish the limits for the region of the genome containing the mutation. The second 
step is the construction of a physical map, consisting of a contiguous, overlapping series 
of genomic clones covering the region of the genome identified in step one (Stubbs, 
1992). The third step in a positional cloning strategy is identifying transcriptional units 
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within the genomic interval of interest and analyzing each of these for suitablilty as a 
candidate for the mutant phenotype (Collins, 1992). 
2. Positional Candidate Approach 
The positional candidate approach, which is a separate but related strategy, has 
been successfully utilized to clone several genes, including those responsible for 
amyotrophic lateral sclerosis (Lou Gehrig's disease), Waardenburg syndrome, and 
Charcot-Marie-Tooth disease (Ballabio, 1993). The positional candidate approach can 
be used when some biochemical or functional information is known about the disease. 
The disease phenotype is mapped in a similar manner to a positional cloning strategy; 
however, it is not necessary to go through the laborious process of producing a physical 
map of the region. Once the disease has been mapped, then the available databases are 
searched for genes and expressed sequence tags (ESTs) mapping into the region, and 
candidate genes are proposed by evaluating likely functional suitability and by looking 
for mutations in their transcripts (Ballabio, 1993). 
3. Mapping Markers in the psrt Region of Mouse Chromosome 7 
The first step in any positional cloning strategy is to identify and map markers 
linked to the mutation to define the limits of the minimal genomic region containing the 
mutation. Any markers identified and mapped in this step can be used to "anchor" the 
physical map (Stubbs, 1992; Collins, 1992). In the mouse, this is readily accomplished 
through the use of polymorphic markers, such as microsatellites (Boehm, 1998). 
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A trans-complementation analysis of the psrt mutation has narrowed down the 
minimal genomic region known to contain the mutation to a region of Mmu 7 bordered 
proximally by the proximal breakpoint of p 2MNURf and bordered distally by the proximal 
breakpoints of p 8°K and p 8R250M, which cannot be resolved at this time (Figure ill-1). 
The p 3RDJOOH deletion does not complement the psrt phenotype; however, its breakpoints 
have not been well defined. An earlier molecular analysis of 36 mutations at the p locus 
determined that the p 3RDJOOH deletes growth arrest 2 ( Gas2), D7H 15F3 7S1, and p, three 
molecular markers, as well as l7Rll, a phenotype-defined marker that maps between 
Gas2 and D7Hl 5F37S1. The proximal breakpoint of the p 3RDJOOH lies in the genomic 
region between Gas2 and ru2, and the distal breakpoint lies between p and Gabrg3 
(Johnson et al., 1995). A subsequent molecular analysis of the p-deletion complex 
mapped fourteen microsatellite markers relative to the previously defined deletion 
breakpoints (Dhar and Johnson, 1997). The microsatellite study, however, included 
only 23 of the p-region deletions; so not all of the deletions utilized for the first study 
were included in the second study. Since the p 3RDJOOH was one of the p-deletions that 
did not complement the psrt phenotype and was not included in the microsatellite study, 
further defining the proximal breakpoint of this deletion may serve to narrow down the 
minimal genomic region known to contain the psrt mutation. 
4. Constructing the Physical Map of the psrt Region 
Constructing a physical map of the minimal genomi~ interval determined to 
contain the gene is the second step in the process of positionally cloning the gene 
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responsible for the psrt phenotype. Generating and fine-mapping new markers in the 
region relative to the deletion breakpoints and to the BAC clones in the region will 
allow the clones to be assembled into a contig covering the region. The clones from the 
contig will then be analyzed to identify transcriptional units, and an expression analysis 
of the psrt and control animals will be used to assess the candidacy of any genes 
identified in the process. 
MATERIALS AND METHODS 
1. Deletion Panel Mapping of Microsatellites 
D7Mit230 and D7Mit312, two microsatellite markers that show size 
polymorphism between Mus musculus and Mus spretus, were mapped by PCR using 
genomic DNAs from interspecific hybrid (Mus musculus X Mus spretus)F 1 carriers of 
various p deletions in which a different Mus musculus p-region deletion chromosome 
was balanced opposite a Mus spretus chromosome (Johnson et al., 1995; Dhar and 
Johnson, 1997). F 1 interspecific hybrids were generated as described previously 
(Johnson et al., 1989). 
Oligonucleotide pnmers for the microsatellite markers were obtained from 
Research Genetics Inc. (Huntsville, AL), and PCRs were performed using a 20 µL total 
reaction volume containing 10-50 ng of template DNA, 2 Units of Taq DNA 
Polymerase (Gibco BRL Life Technologies, Inc.; Gaithersburg, MD), 0.6 µM each 
primer (forward and reverse), and 14 µL of PCR mix to give a final concentration of 1.5 
mM MgCli and 1 X PCR buffer. Reactions were carried out in 0.2 mL PCR tubes using 
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a PTC-100 thermocycler (MJ Research, Waltham, MA) and the following program: 
initial denaturation at 94°C for 5 minutes followed by 30 cycles of denaturation at 94°C 
for 45 seconds, annealing at 45°C for 45 seconds, and extension at 72°C for 150 
seconds, then a final five minute extension step at 72°C. PCR products were analyzed 
on 3% NuSieve GTG agarose gels (FMC Bioproducts, Rockland, ME) made with lX 
TAE (0.04 M Tris-acetate, 0.001 M EDTA) and visualized under UV light after staining 
with ethidium bromide. 
2. Defining the Breakpoints of p 3RD3ooH 
The breakpoints of p3RD3ooH were defined by PCR amplification of eight 
microsatellite markers using genomic DNA from interspecific hybrid (Mus musculus X 
Mus spretus )F 1 carriers of the p3RD3oon deletion. The eight microsatellite markers used 
were D7Mit26, D7Mit69, D7Mit70, D7Mit84, D7Mit145, D7Mit160, D7Mit193, and 
D7Mit230. Reactions were performed, and PCR products were analyzed, as described 
above. 
3. BAC Library Screenings 
The Genome Systems, Inc. (St. Louis, MO) "Down to the well" Mouse (strain 
129SV) ES BAC DNA pools were screened by PCR using primers for D7Mit145, 
D7Mit193, D7Mit194, and D7Mit230. The reactions were performed using 3 µL of the 
BAC superpool DNA in a 20 µL total reaction volume, using the same reagents and 
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thermocycling program as described above, annealing at 45°C (or 48°C for D7Mit145) 
for 35 cycles. PCR products were analyzed as described above. 
The Genome Systems, Inc. (St. Louis, MO) BAC Mouse Library (Release II) 
high density filters were also screened by hybridization using RT 591/592, a 287 bp 
RT-PCR product from the mouse Prmt3 cDNA. The generation and analysis of this 
RT-PCR product is described in detail in Chapter VI (Sequence and Expression 
Analyses of Candidate Genes). Standard hybridization conditions were utilized, and 
blots were washed three times, with a final 20 minute wash at 65°C in 0.1 X SSCP. 
BACs screened by hybridization were confirmed by PCR, using primer pair ORN 
591/592, annealing at 50°C for 35 cycles. BACs were grown in LB medium plus 
chloramphenicol (12.5 µg/mL) and BAC DNA was isolated using either the Promega 
Wizard® Plus Minipreps DNA Purification System (Promega Corporation, Madison, 
WI) or the Qiagen Plasmid Midi Kit (Qiagen Inc., Valencia, CA) according to the 
manufacturer's instructions. 
4. Determining the Size ofBAC Inserts 
BACs were grown and the DNA was isolated as described above. BAC DNAs 
were digested overnight at 37°C with Natl (Gibco BRL Life Technologies, Rockville, 
MD) using the following reaction cocktail: 1 0µL of miniprep or midiprep DNA, 2.5 µL 
of 10 X React3 and 2 µL (15 units/µL) Natl (Gibco BRL Life Technologies, Rockville, 
MD), and 10.5 µL of sterile water. Digested DNAs were loaded on a 1 % agarose gel 
which was run in 0.5X TBE at 14°C. Electrophoresis was performed in a BioRad Chef 
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Mapper pulsed field gel electrophoresis (PFGE) apparatus using the autoalgorithm 
function programmed to separate fragments ranging from 50-kb to 500-kb. The gel was 
stained with ethidium bromide and visualized under UV light. The size of the inserts 
was determined by comparison to low-range and mid-range PFGE markers (New 
England Biolabs, Beverly, MA). 
5. BAC Endcloning and STS Generation 
STSs were generated from the terminal sequences of the BACs usmg a 
modification of the ligation linker PCR method (Riley et al., 1990; Mueller and Wold, 
1989). Briefly, the BAC is digested with several different restriction enzymes, an oligo 
linker is ligated to the fragments, and PCR is performed on the digested fragments using 
primers for the oligo linker and either the SP6 or T7 promoter sequences, which are in 
the BAC vector near the cloning site (Shizuya et al., 1992; Kim et al., 1996). STSs 
were also generated from internal sequences by single primer PCR using primers for the 
Bl and B2 repeat sequences in the mouse (Kim et al., 1997a). 
The PCR products obtained were cloned using the pGEMT-Easy II cloning kit 
(Promega Corporation, Madison, WI) and analyzed by fluorescent sequencing with the 
Big Dye Terminator Kit (PE Biosystems, Foster City, CA). The products were run on 
an ABI377 DNA sequencer and the sequence analyzed using BLAST 
(http://www.ncbi.nlm.nih.gov/BLAST/) to verify the identity of the cloned products. 
STS clones were verified by mapping back to the p-region of Mmu 7 using deletion 
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panel Southern blots and standard hybridization protocols (Johnson et al., 1995; Dhar 
and Johnson, 1997). 
6. Placing STSs on the Physical Map 
STSs were placed on the physical map in one of two ways: by PCR or by 
hybridization. Nine microsatellite markers (D7Mit26, D7Mit69, D7Mit70, D7Mit84, 
D7Mit145, D7Mit160, D7Mit193, D7Mit229 and D7Mit230) and one EST (RT 
591/592) were amplified by PCR using BAC miniprep DNAs and conditions described 
above (D7Mit229 was annealed at 40°C for 35 cycles). D7Mit229 was used with the 
BAC DNAs, but not for mapping with the deletion panels, because it is not polymorphic 
between Mus musculus and Mus spretus. BACs positive for the STS will show an 
amplification product of the expected size. 
Other STSs were placed on the physical map by hybridizing to Southern blots of 
BAC DNAs digested with EcoRV. BACs positive for the probe show a hybridization 
band of the appropriate size in the autoradiograph of the washed blot. Seven STSs were 
placed on the physical map by hybridization, including four BAC end clones 
(B36n 10/EcoRV /SP6, B36n10/EcoRV/T7, B 1 79d 14/EcoRV /SP6, and 
Bl 79d14/EcoRV/T7), and two RT-PCR products from the Prmt3 gene, RT 595/596 and 
RT 591/592, which was also mapped by PCR (Table IV-1, in the Appendix). 
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7. Deletion Panel Mapping of Probes 
STS clones and other probes showing a restriction fragment length 
polymorphism (RFLP) between Mus Musculus and Mus spretus were verified by 
mapping to the p-deletion complex by hybridization using deletion panel Southern blots 
and standard hybridization protocols (Johnson et al., 1995; Dhar and Johnson, 1997). 
Probes were isolated on 1 % LMP (low melt point) Agarose (Gibco BRL, Rockville, 
MD) then melted and random prime labeled with [a-32P]dCTP. Hybridizations were 
performed at 42°C overnight, and blots were washed three times: 20 minutes at room 
temperature in 2X SSCP with 0.1 % SOS, followed by 20 minutes at 65°C in 2X SSCP 
and 20 minutes at 65°C in 0.lX SSCP. The following probes were mapped by 
hybridization to deletion panel blots: B36n10/B2A, B4514/Pvu/T7, Bl 79dl4/B1B, 
Bl 79d14/EcoRV/SP6, Bl 79dl4/EcoRV/T7, RT 591/592. 
RESULTS 
1. Deletion Panel Mapping of Microsatellites 
In order to better define the region of the genome surrounding the psrt locus, 
two microsatellite markers were mapped. A PCR analysis of D7Mit230 using the 
deletion panel DNAs shows that the Mus musculus band is absent for p 46DFiOD, p 47DTD, 
p 2MNURf, and p 3RD3ooH, while it is present in p 8°K and p 8RisoM_ The absence of the Mus 
musculus band indicates that the marker is deleted; therefore, the marker must lie 
between the proximal breakpoints of p2MNURJ and p 3RDJOOH (which are unresolved at this 
time) andp 8°K andp 8RlJOM (which are also unresolved). A similar analysis of D7Mit312 
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shows that the Mus musculus band is present for all six deletion DNAs, which means 
that the marker is not contained within the deleted region for any of the six deletions 
tested. Therefore, D7Mit312 must map outside the p-deletion complex (Figure IV-2). 
2. Defining the Breakpoints of p 3RD3ooH 
PCR analysis of eight microsatellite markers in the p-deletion complex has 
further defined the breakpoints of p 3RDJOOH_ Three of the microsatellite markers tested 
were deleted in p 3RDJOOH: D7Mit193, D7Mit230, and D7Mit145. Five of the 
microsatellite markers were not deleted: D7Mit26, D7Mit69, D7Mit70, D7Mit84, and 
D7Mitl 60. This means that the proximal breakpoint of p3RDJOOH is between D7Mit26 
and D7Mit69 (which cannot be resolved at this time) and D7Mit193 and D7Mit230 
(which also cannot be resolved). Previously, the proximal breakpoint of this deletion 
was known to be somewhere between Ldh3 and Gas2 (Johnson et al., 1995). The distal 
breakpoint of the p 3RDJOOH deletion is between D7Cwrl 5 and D7Mit84. Previous 
mapping studies indicate that the p3RDJOOH deletion encompasses the D7HJ 5F37S1 locus 
(Johnson et al., 1995) and the D7Mit70 locus maps proximal to D7H15F37S1, between 
D7HJ 5F37S1 and D7Mit196 (Wu et al., 2000). These data indicate that D7Mit70 is not 
deleted in p 3RD300H, meaning that p 3RD3ooH is a "skipper," which is a noncontiguous 
deletion most likely involving some sort of complex rearrangement (Johnson et al., 
1995) (Figure IV-3). 
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3. BAC Library Screenings 
A total of eleven BACs from the Genome Systems, Inc. (St. Louis, MO) "Down 
to the well" Mouse ES BAC DNA pools were screened by PCR using primers for four 
different microsatellite markers mapping near the psrt region. There were four BACs 
selected using microsatellites mapping within the psrt minimal interval: three positive 
for D7Mit193 (B36nl0, B4514, and B179dl4) and one positive for D7Mit230 (B21 li3). 
In addition, D7Mit145, the microsatellite marker mapping in the distally adjacent 
deletion interval, was used to identify two BACs (B207pl 7 and B212f2). D7Mit194, 
which maps in the most proximal deletion interval and may be useful in cloning ru2, 
was used to select five BACs (B47g18, B47g22, B142k10, B142k22, and Bl 78n12). 
There were also twelve BACs from the Genome Systems, Inc. (St. Louis, MO) 
BAC Mouse Library (Release II) high density filters that were identified by 
hybridization using RT 591/592, a 287 bp RT-PCR product from the mouse Prmt3 
cDNA, as the probe. They are: B242g12, B279114, B288k21, B315k22, B329d6, 
B333e23, B34416, B354kl 1, B372t7, B382013, B434g10, and B462a15. These BACs 
were confirmed by PCR using four different sets of primers: RT 591/592, which was 
used to amplify the RT-PCR product that was used to screen the library; D7Mit193, 
which maps in the psrt minimal interval; ORN 609/610, which corresponds to the T7 
end of B4514; and ORN 607/608, which corresponds to the terminal sequence of 
B 179d 14. The BA Cs were then subdivided into categories based on the results of the 
PCRs (Table IV-4). 
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4. Deletion Panel Mapping of STSs 
Deletion panel Southern blots were used to map probes showing an RFLP 
between Mus musculus and Mus spretus. Seven probes were mapped this way, 
including three BAC end clones (B36nl0/EcoRV/SP6, Bl 79dl4/EcoRV/SP6, and 
Bl 79dl4/EcoRV/T7), and two STSs derived from single-primer PCR (B36nl0/B2A 
and B 179d 14/B 1 B). In every instance, the Mus mus cu/us bands are present in p 8°K and 
PBR250M and absent inp46DFiOD,p47DTD,p3RD300H andp2MNURf, which means that the probes 
are deleted in in p46DFiOD, p47DTD, p3RD300H and p2MNUR~ but not in in PBOK and PBR250M_ 
Therefore, these seven probes must map proximal to the p 8°K and p 8R250M proximal 
breakpoints and distal to the p 3RD300H and p 2MNURf proximal breakpoints, which is the 
genomic region identified as the psrt minimal deletion interval (Figure IV-5). 
There were two STSs that appear to contain repetitive sequences because they 
showed smears rather than distinct hybridization bands. Therefore, these STSs could 
not be used as probes for hybridization and no mapping results could be obtained for 
them. They are: B4514/Rsa/SP6 and B21 li3/EcoRV/T7a. 
5. BAC Insert Sizes 
PFGE was used to determine the insert size of six of the BACs used to produce 
the physical map. The six BACs and their calculated insert sizes are: B36n10 (120-kb), 
B4514 (120-kb), Bl 79dl4 (150-kb), B207pl 7 (280-kb), B21 li3 (125-kb), B212f2 (190-
kb ). Four of the BACs have a single internal Natl restriction site (B36nl 0, B4514, 
Bl 79d14, and B21 li3), one BAC has two sites (B207pl 7), and one has zero (B212f2) 
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(Table IV-6). All of the BACs whose insert size was determined were from the 
Genome Systems, Inc. (St. Louis, MO) "Down to the well" Mouse ES BAC DNA 
pools. 
6. Assembly of the Physical Map 
The physical map was assembled by identifying the markers present on each of 
the clones, checking for overlap of the markers on the BA Cs, then ordering them into a 
contig. The map consists of thirteen BA Cs, seven from the "Down to the well" Mouse 
ES BAC DNA pools, and six from the BAC Mouse Library (Release II) high density 
filters. The insert sizes of the BACs from the latter were not determined. Two sets of 
BACs were determined to contain the same markers: B315k22, B372f7 and B382o13 
all contain RT 591/592 and ORN 607/608; and B242g12, B288k21, B34416, and 
B462a15 all contain D7Mit193, ORN 609/610, and ORN 607/608. To minimize 
redundancies, only one of the BACs from each of these two groups is included in the 
map (Figure IV-7). 
DISCUSSION 
Fine-mapping the endpoints of the p 3RDJOOH deletion places the proximal 
breakpoint between the same two sets of microsatellite markers as the p 2MNURf deletion. 
Since both p 3RD3ooH and p 2MNURJ fail to complement the psrt phenotype, their proximal 
endpoints (which cannot be resolved at this time) must define the proximal limit of the 
minimal genomic interval determined to contain the psrt mutations. The distal limit of 
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the interval is defined by the proximal breakpoints of p 8°K and p 8R250M. Therefore, the 
physical map should cover the entire minimal region, from the proximal breakpoints of 
p3RDJOOH and p 2MNURf to the proximal breakpoints of p 8°K and p 8R250M, to ensure that the 
psrt transcriptional unit is included. 
The current physical map of the region does not completely span the psrt 
minimal region because there is not uninterrupted coverage from one end of the 
minimal region to the other (Figure IV-7). The physical size of the region is unknown; 
therefore, it is impossible to know how complete the map is at this time. The map does, 
however, contiguously span an area within the psrt minimal genomic region that 
includes three microsatellite markers and ten molecular probes (Figure IV-7). The 
physical map, while not complete, provides a number of BAC clones that can be 




SEQUENCE ANALYSIS OF BAC B179dl4 AND IDENTIFICATION 
OF CANDIDATE GENES 
ABSTRACT 
Sequence analysis of BAC B 179d 14 has identified two candidate genes for the 
psrt phenotype: Tat-interacting protein (30 kD) (Tip30) and protein arginine N-
methyltransferase (Prmt3). A third candidate gene, glycine transporter type 2 ( G/yt2), 
was identified because of its location in the human genomic region of homology and its 
function in neurotransmission. The sequence of BAC B 179d 14 was used to determine 
the structure of a 150-kb genomic interval containing the mouse Tip30/Cc3 and Prmt3 
genes. 
INTRODUCTION 
The process of identifying candidate genes is an important part of any positional 
cloning or positional candidate strategy. These two strategies are related and can be 
complementary. The positional cloning approach differs from the positional candidate 
approach in that positional cloning involves the laborious step of producing and 
assembling a physical map of the genomic region determined to contain the mutation, 
followed by a search for transcriptional units within the region (Collins, 1992). The 
positional candidate approach, on the other hand, can be utilized when some 
biochemical or functional information is known about the disease. Transcriptional 
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units are identified through searching the available databases for genes and ESTs 
mapping into the region (Ballabio, 1993). Once candidate genes have been identified 
using either approach, expression and sequence analyses are required to evaluate the 
validity of their candidacy by determining if mutations exist in the transcripts (Collins, 
1992; Ballabio, 1993). Since some information is known about the psrt phenotype, it is 
possible to utilize both the positional cloning and positional candidate approaches to 
identify and clone the gene responsible for psrt. 
Once the physical map is assembled, it is necessary to isolate and identify 
transcriptional units in the genomic (BAC) clones that compose the physical map. 
There are numerous techniques available for this purpose (Parimoo et al., 1995). They 
range from splicing signal-based methods such as exon trapping (Duyk et al., 1990; 
Krizman and Berget, 1993) and exon amplification (Buckler et al., 1991; Church et al., 
1994) to methods relying on the identification of either CpG islands or phylogenetically 
conserved sequences (Parimoo et al., 1995) to cDNA selection (Parimoo et al., 1991) 
and direct selection (Lovett et al., 1991) to sequence and computational-based methods 
utilizing DNA sequencing (Claverie, 1994) and analysis of the sequence utilizing 
programs such as the gene recognition and analysis internet link (GRAIL) (Uberbacher 
and Mural, 1991). 
The method chosen for this project was random shotgun DNA sequencing 
followed by computer analysis of the sequence to detect transcriptional units. 
Sequencing was done by randomly fragmenting the original BAC clone and subcloning 
the fragments into a vector that is easily sequenced. A comparison of the sequencing 
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results will identify overlap, which can be used to assemble the sequences into contigs. 
Contigs are screened for repetitive elements and the sequence is analyzed for 
transcriptional units (Claverie, 1994). 
This project was accomplished using a combination of the positional cloning 
strategy and the positional candidate approach. A search of the databases occurred 
concomitantly with the development and assembly of the physical map in an effort to 
identify the gene responsible for the psrt phenotype. 
MATERIALS AND METHODS 
1. Selecting a BAC for Sequencing 
The BAC clone chosen for sequencing was B 179d 14, from the Genome 
Systems, Inc. (St. Louis, MO) "Down to the well" Mouse ES BAC DNA pools. 
Bl 79d14 was one of the first group of BACs screened, and was selected using 
D7Mit193, which maps in the same deletion interval as the psrt phenotype. Its size, 
determined by PFGE, is approximately 150-kb. There are seven STSs contained on 
Bl 79d14 that have been fine-mapped back to the psrt minimal region, and three other 
STSs that could not be mapped to the deletions (because they do not show an RFLP 
between Mus muscu/us and Mus spretus) but were mapped to BAC clones in the region. 
This means that Bl 79dl4 is most likely not chimeric, because it contains ten molecular 
markers within 150-kb that map to the same deletion interval. 
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2. BAC DNA Purification, Subcloning, and Sequencing 
BAC DNA was isolated using the Qiagen Mega Prep Kit (Qiagen Inc., Valencia, 
CA) according to the manufacturer's instructions, except using double the 
recommended volume for solutions Pl, P2, and P3. The BAC DNA was further 
purified through two cycles of CsCl gradient centrifugation (Sambrook et al., 1989). 
Approximately 20% of the DNA was then sheared using a Gene Machine Hydroshear 
on a setting of eight, and the sheared DNA was treated with T4 Polymerase to make 
blunt ends. The sheared, blunt ended DNA was ligated into the pBSK- vector 
(Stratagene Inc., La Jolla, CA) that had been EcoRV digested and phosphatased. The 
ligated DNA was electroporated into E. coli DH5a cells (Gibco BRL Life 
Technologies, Rockville, MD) and putative transformants were selected on LB plus 
Ampicillin (100 µg/mL) plates. 
Plasmid DNA from the subclones was isolated on a Qiagen BioRobot 9600 
using the QIAprep 96 Turbo BioRobot Kit (Qiagen Inc., Valencia, CA). The templates 
were then sequenced using either the Dye Primer or Big Dye Terminator Kits (PE 
Biosystems, Foster City, CA) and the products run on an ABI377 DNA sequencer. 
3. Analysis of Sequence Data 
Sequence data were processed and assembled using the Phred, Phrap, and 
Consed package of progams on an SGI 02 workstation. Approximately 2,440 subclones 
were sequenced to produce approximately 8X coverage. Repeat sequences were 
identified using RepeatMasker (University of Washington, Seattle, WA). Additional 
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analyses were performed using either the Wisconsin Package of programs, Version 10 
(Genetics Computer Group, Madison WD, the Genome Channel software (ORNL, Oak 
Ridge, TN; http://www.genome.ornl.gov) or the NCI BLAST program 
(http://www.ncbi.nlm.nih.gov/BLAST). 
4. Database Search for Positional Candidates 
The human genome sequencing database at the National Center for 
Biotechnology Information (NCBD was searched for candidate genes mapping within 
the (human) llp14-p15 genomic interval, which is homologous to the psrt region of 
Mmu 7. The database 1s located at the NCBI website 
(http://www.ncbi.nlm.nih.gov/genome/seq). Genes mapping in the 1 lp14-p15 interval 
were accessed by following the "human genome resources" link, selecting chromosome 
11, and scrolling to the 11 p 14-p 15 interval and zooming in or out, as necessary. There 
are links for every gene listed which will open a new page with information and links 
on the gene symbol, locus information, map information, NCBI reference sequence, 
GenBank sequences, and annotations. 
RESULTS 
1. Candidate Gene Identification 
There were two genes identified from a BLAST search of the repeat-masked 
sequence data from BAC Bl 79dl4: the human Tat-interacting protein (30kD), TIP30 
(Genbank accession # NM_006410), and the Rattus norvegicus protein arginine N-
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methyltransferase 3, Prmt3 (Genbank accession # AF059530). A search of the human 
genome sequencing database identified several genes in the human 11 p 14-p 15 interval. 
Although no known human disease genes were found to map within this interval, the 
glycine transporter type 2 (GLYT2) gene (Genbank accession # AF085412) was 
identified as a positional candidate because of its function in neurotransmission. 
2. Structure of the Insert ofBAC Bl 79dl4 
The insert of BAC Bl 79d14 is approximately 150-kb in length, as determined 
by both PFGE and sequencing data. It contains Tip30/Cc3 and Prmt3, both of which 
are transcribed in the same direction, separated by approximately 5-kb of genomic 
sequence. The Tip30/Cc3 gene is approximately 15-kb in length, while the Prmt3 gene 
is approximately 85-kb. There is a single Natl restriction site in the CpG island near the 
5' end of Prmt3, and D7Mitl93 is located just 5' of Tip30/Cc3. There is approximately 
25-kb of sequence 5' of Tip30/Cc3, and approximately 20-kb of sequence 3' of Prmt3 
(Figure V-1). 
3. Genomic Structure of the Tip30/Cc3 Gene 
The murine Tip30/Cc3 gene is composed of five exons spanning approximately 
15-kb of genomic sequence. The exons range in size from 62 to over 200 bp in size, 
and the introns range from 660 bp to approximately 8-kb (Table V-2). 
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4. Genomic Structure of the Prmt3 Gene 
The murine Prmt3 gene is composed of 16 exons spanning approximately 85-kb 
of genomic sequence. The exons range from 51 hp to 188 hp in size, and the introns 
range from 80 hp to over 19-kb (Table V-3). 
DISCUSSION 
BAC B 179d 14 was chosen for sequencing for several reasons. It was one of the 
first BA Cs screened; as such, it has been well characterized. Both ends of the BAC, as 
well as an internal STS, have been cloned and fine-mapped to the p-deletion complex. 
It is a fairly large clone, with an insert size of approximately 150-kb. And it is most 
likely not chimeric, because it contains nine molecular markers within its 150-kb insert 
that map to the same deletion interval. 
The genomic sequence of Tip30/Cd has not been published; however, a similar 
cDNA, named Td (for truncated Cd), has been described (Genbank accession # 
AF092095). The TC3 and CC3 proteins share a similar N-terminal domain; however, 
TC3 has a unique, shorter C-terminus. While Cc3 is a tumor suppressor that functions 
through activation of the apoptotic pathway, Tc3 is a tumor promoter that strongly 
inhibits apoptosis. It has been postulated that Cd and Td are alternatively spliced 
transcripts from the same genomic locus (Whitman et al., 2000). Data from this project, 
however, dispute this claim. A full 110-kb of genomic sequence downstream of 
Tip30/Cd has been sequenced in this BAC, and the unique portion of the Td transcript 
is not present in this sequence in mouse. This 110-kb of sequence includes the 5-kb 
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intergenic space between Tip30/Cc3 and Prmt3, the 85-kb that comprises the Prmt3 
gene, and 20-kb of sequence downstream of Prmt3; therefore, it is unlikely that 
Tip30/Cc3 and Tc3 are alternatively spliced transcripts arising from the same genomic 
locus. 
Sequence analysis of BAC B 179d 14 has provided two candidate genes for the 
psrt phenotype, Tip30/Cc3 and Prmt3. A search of the human genome sequencing 
database in llp14-15, the region of homology, has provided one additional candidate 
gene: GLYT2. Two of these genes have been evaluated for their suitability as 
candidates for the psrt phenotype. All three of these candidates are described in detail 
in Chapter VI (Description of Candidate Genes). 
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CHAPTER VI 
DESCRIPTION OF CANDIDATE GENES 
INTRODUCTION 
There are three candidate genes that have been identified for the psrt phenotype: 
Tat-interacting protein 30 kDA (Tip30), glycine transporter type 2 (Glyt2), and protein 
arginine N-methyltransferase 3 (Prmt3). What follows is a description of each of the 
three candidates, and a discussion of the function of the proteins encoded by these 
genes. 
Tat-interacting protein 30 kDa (TIP30) 
Tat-interacting protein 30 kDa (TIP30) is a cellular protein that interacts with 
the trans-activator of transcription (TAT) protein, a transcription factor encoded by 
HIV-1 (Xiao et al., 1998). TAT promotes transcriptional elongation by RNA 
polymerase II (RNAP II) and requires multiple cofactors, including TIP30, CDK 9, 
cyclin T, Tat-SFl, P-TEFb, TFIIH, TAK, (human) SPT5, and CA150 (Herrman and 
Rice, 1995; Zhou and Sharp, 1995; Cujec et al., 1997; Keen et al., 1997; Sune et al., 
1997; Xiao et al., 1998; Yank:ulov and Bentley, 1998; Zhou et al., 1998; Jeang et al., 
1999; Kim et al., 1999). Tat is unique in that it binds to an RNA, rather than a DNA, 
ligand during transcription (Zhou and Sharp, 1995; Parada and Roeder, 1996). Tat 
binds to TAR, the trans-activation response region, which is a stem-loop structure near 
the initiation site of the HIV-I transcript (Zhou and Sharp, 1995; Yank:ulov and Bentley, 
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1998). Tat has been shown to have other functions as well, including an involvement in 
HIV -1 reverse transcription (Harrich et al., 1997). 
TIP30 is a member of the short-chain dehydrogenase/reductase (SDR) family 
(Baker, 1999). It contains a pap fold near the amino terminus as well as other 
structural features conserved among members of the SDR family (Baker et al., 2000). 
TIP30 is the same as the protein called CC3, a known suppressor of metastasis (Liu et 
al., 1999; Shtivelman, 1997). Human CC3 is ubiquitously expressed in tissues as well 
as in various cell lines, including the classic small cell lung carcinoma ( c-SCLC) cell 
line. However, no CC3 expression has been demonstrated in variant small cell lung 
carcinoma (v-SCLC) cell lines, which exhibit very aggressive metastatic behavior. It 
has been hypothesized that CC3 functions as a tumor suppressor by promoting 
apoptosis (Shtivelman, 1997). TIP30/CC3 has recently been identified as a 
serine/threonine kinase, and is involved in the Tat-dependent phosphorylation of the C-
terminal domain of the largest RNAP II subunit. This kinase activity is necessary for 
TIP30/CC3 to function both as a transcriptional cofactor and in regulating apoptosis 
(Xiao et al., 2000). 
The genomic sequence of Tip30/Cc3 has not been published; however, a similar 
cDNA, named TC3 (for truncated CC3), has been described in human. The TC3 and 
CC3 proteins share a similar N-terminal domain; however, TC3 has a unique, shorter C-
terminus. While CC3 is a tumor suppressor that functions through activation of the 
apoptotic pathway, TC3 is a tumor promoter that strongly inhibits apoptosis. The TC3 
protein is highly unstable and, therefore, short lived. It has been postulated that CC3 
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and TC3 arise from alternatively spliced transcripts from the same genomic locus since 
a large portion of their N-terminal domains are identical (Whitman et al., 2000); 
however, sequencing data from this project dispute this claim. 
Glycine transporter type 2 (GLYT2) 
Neurotransmitter transporters are membrane-bound proteins located either in the 
plasma membrane or in the synaptic vesicle membrane. There are three types of these 
transporters: the Na+/CC and K+/Cl- dependent transporters located in the plasma 
membrane, and the pH or H+ -dependent transporters located in the membrane of the 
synaptic vesicle (Lesch et al., 1996). Neurotransmitter transporters establish and 
mediate the interplay between excitation and inhibition, and abnormal neurotransmitter 
transport has been shown to cause nerve dysfunction and damage (Liu and Edwards, 
1997; Morrow et al., 1998). Glycine transporter type 2 (GlyT2) is a member of the 
Na+/Cr dependent family of neurotransmitter transporters and is one of two glycine 
transporters identified in humans. It is involved in the reuptake of glycine at the 
synaptic cleft through a ligand-gated Cl- channel (Amara & Kuhar, 1993 cited in 
Aubrey et al., 2000; Morrow et al., 1998). 
Glycine and y-aminobutyric acid (GABA), the maJor inhibitory 
neurotransmitters of the vertebrate brain stem and spinal cord, keep the postsynaptic 
membrane polarized, thereby suppressing synapse firing. In contrast, glutamate and 
other excitatory neurotransmitters function to open Na+ channels and depolarize the 
presynaptic membrane until the action potential is reached and the synapse fires 
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(Reckling et al., 2000; Alberts et al., 1996). GABA and glycine are both considered 
fast neurotransmitters because of their kinetics; however, the kinetics of GABA 
suppression is different from glycine suppression, since GABA has a more prolonged 
effect than glycine (Nicoll and Malenka, 1998). Although they have separate receptors 
and transporters, GABA and glycine are co-released from the same vesicles at the 
inhibitory synapses of spinal neurons (Jonas et al., 1998). 
The GL YT2 protein contains six consensus protein kinase C-dependent 
phosphorylation sites as well as five N-linked glycosylation sites (Martinez-Maza et al., 
2001; Morrow et al., 1998). It has been demonstrated that the glycosylation status of 
the protein affects its subcellular localization (Martinez-Maza et al., 2001). Like other 
members of the Na+ /Cr dependent neurotransmitter transporter family, GL YT2 contains 
12 transmembrane domains, with domain ill being primarily responsible for the 
transport activity of both the substrate and the co-transported Na+ and er ions (Ponce et 
al., 2000). GL YT2 co-localizes with the strychnine-sensitive glycine receptors in the 
brain stem, spinal cord, and cerebellum (Morrow et al., 1998; Aubrey et al., 2000). It 
co-immunoprecipates with Syntaxin IA, a SNARE (soluble N-ethylmaleimide-sensitive 
factor attachment protein receptor) protein involved in both intracellular membrane 
trafficking and the regulation of various ion channels. Syntaxin IA has also been 
shown to interact with GATl, a GABA transporter, and GLYTl, a type-I glycine 
transporter. When GL YT2 is bound to syntaxin IA, the normal GL YT2 protein 
trafficking pattern in the cell is upset. This causes GlyT2 to be improperly distributed 
in the plasma membrane, thereby interfering with the transport of glycine (Geerlings et 
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al., 2000). Furthermore, a yeast two-hybrid analysis using GlyT2 as bait has identifed 
unc-33 like phosphoprotein 6 (Ulip6) as a protein interacting with GL YT2. Ulip6 is 
expressed in embryonic and postnatal brain and spinal cord and is believed to be 
involved in neuronal differentiation and axon growth (Horiuchi et. al., 2000). 
Therefore, GL YT2 is a protein involved in neural development and function in several 
ways. 
In humans, the GLYT2 gene produces a single, 9.5-kb mRNA transcript detected 
by northern hybridization in medulla, cerebellum, and spinal cord (Morrow et al., 
1998). The gene maps to human chromosome llp15.1-15.2 (Morrow et al., 1998), 
which is homologous to the psrt region of Mmu 7. Several polymorphisms have been 
reported in the human gene; however, the effect(s) of these polymorphisms on 
neurophysiology is unknown (Evans et al., 1999). 
Protein arginine methyltransferase 3 (Prmt3) 
A thorough discussion of Prmt3 as a candidate for the psrt phenotype should 
include an overview of the process ofmethylation. What follows is such an overview, 
with a description of enzymatic methylation in general followed by a review of protein 
arginine methylation, including a discussion of the functional roles of the process at the 
cellular and organismal levels, as well as in vivo substrates and protein arginine 
methyltransferase enzymes. 
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1. Enzymatic Methylation 
Methyltransferases are an important class of enzymes that catalyze the transfer 
of a methyl group to a substrate. The universal methyl donor for these reactions is S-
adenosylmethionine (AdoMet, or SAM), which is a methionine with an adenosine 
attached to the sulfur atom on the side chain; however, there are many types of methyl-
accepting substrates. DNA methyltransferases are a well-studied class of enzymes 
responsible for methylating various positions on cytosine and adenine nucleotides 
(Bussiere et al., 1998; Labahn et al., 1994). A methyltransferase that modifies mRNA, 
and two small molecule methyltransferases that modify catechol and glycine, have also 
been described (Bussiere et al., 1998). Several types of protein methyltransferases are 
known, as well (Gary and Clarke, 1998). 
Despite the diversity of functions performed and substrates utilized by the 
different methyltransferase enzymes, all known AdoMet-dependent methyltransferases 
operate via a SN2 (bimolecular nucleophilic substitution) reaction mechanism (Zhang et 
al., 2000). They contain a signature methyltransferase domain composed of four 
conserved regions of homology: motifs I, post-I, II, and III. These motifs are 
responsible for binding AdoMet and catalyzing the methyl transfer (Weiss et al., 2000). 
They appear in the same order and are separated by a characteristic number of residues. 
Motifs I and post-I are involved in AdoMet binding, motifs II and III interact with each 
other, and motifs I, II, and III are involved in forming the central 13-sheet, a structural 
element common to all methyltransferases (Niewmierzycka and Clarke, 1999). 
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2. Protein Methylation 
In eukaryotes, proteins can be methylated either on the oxygen molecule in the 
carboxyl group or on the nitrogen molecule(s) in the side chain. Only three amino acid 
residues are modified in eukaryotes by methylation: arginine, histidine, or lysine 
(Aletta et al., 1998; Sundarraj and Pfeiffer, 1973; Gary and Clarke, 1998). In 
prokaryotes, it has been shown that a methyl group can be transferred via an 
esterification reaction to the y-carboxyl group of glutamic acid residues (Aletta et al., 
1998). 
There have been three types of protein methylases described: those that transfer 
the methyl group (from AdoMet) to an arginine residue in the substrate, those that 
transfer it to a C-terminal carboxyl group of a histidine residue, and those that transfer 
the methyl group to the E-amino group of a lysine residue. These are called protein 
methylase I, II, and III, respectively (Sundarraj and Pfeiffer, 1973) (Figure VI-1 ). 
Protein methylase I, a protein arginine methyltransferase (PRMT), is the enzyme 
responsible for methylating any of the guanidino nitrogens present in arginine residues. 
PRMT genes have been identified and cloned in several organisms, including human, 
Saccharomyces cerevisiae and Schizosaccharomyces pombe, Arabidopsis, and 
Caenorhabditis elegans. In addition, expressed sequence tags (ESTs) from at least six 
other organisms (including Drosophila melanogaster, Xenopus laevis, sea urchin and 
zebrafish, as well as rice and tomato) show similarity to PRMTs (Zhang et al., 2000). 
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3. Functional Roles of Arginine Methylation 
The precise biochemical role that protein arginine methylation plays in the cell 
has not yet been determined; however, it is believed to be responsible, at least in part, 
for a variety of processes. Most of the known in vivo targets of protein arginine 
methylation are proteins involved in some way with RNA, either through directly 
binding the RNA or through involvement with the ribosome (Najbauer et al., 1993; Liu 
and Dreyfuss, 1995; Gary and Clarke, 1998). Certain proteins contain an RGG (or 
GAR) domain, which has an abundance of arginine and glycine residues and is the 
specific substrate for several protein arginine N-methyltransferases. This domain has 
been shown to modulate protein-protein and protein-nucleic acid interactions (Bouvet et 
al., 1998; Gary and Clarke, 1998). Methylarginine-containing domains have also been 
shown to be responsible for the binding specificity of certain proteins (Plotnikov et al., 
2000). It has been postulated that the presence of methylarginine residues could affect 
the dynamics of ligand-substrate interactions, altering either the stereochemistry of the 
process, the hydrogen bonding interactions occurring between the modified protein and 
its substrate(s), or both (Mears and Rice, 1996). Therefore, the methylation of arginine 
residues is believed to play a role in the intermolecular dynamics of ligand-substrate 
binding, including both protein-nucleic acid and protein-protein interactions. 
The modification of arginine residues has also been shown to affect a protein's 
susceptiblilty to proteolysis. Methylated heterogeneous nuclear ribonuclear protein Al 
(hnRNP Al) is more susceptible to trypsin digestion than the unmethylated protein 
(Rajpurohit et al., 1994a), while the methylated forms of other hnRNPs have been 
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shown to confer resistance to proteolytic cleavage (Bedford et al., 2000). The myelin 
basic protein (MBP) normally contains 19 arginine residues, only one of which is 
modified by methylation. It has been shown that MBP containing this single 
methylarginine residue is more resistant to trypsin digestion than is the unmethylated 
MBP (Brostoff and Eylar, 1971). On the other hand, MBP containing citrullines in 
place of the methylarginine and the other unmodified arginines is proteolytically 
degraded by cathepsin D more quickly than the non-citrullated MBP. Citrulline, like 
methylarginine, is a posttranslationally modified arginine; however, citrulline is 
modified by deamidation, a different process. Furthermore, there is a positive 
correlation between number of citrulline residues in the protein and the rate of 
enzymatic degradation (Cao et al., 1999). Therefore, the modification of arginine 
residues, either through the process of protein arginine methylation or through 
deamidation, can effectively and substantially alter the protein-protein interactions 
involved in catalytic proteolysis. 
Protein arginine methylation has also been shown to be involved in subcellular 
localization. Proteins containing methylarginine residues are found in various 
compartments within the cell: some are located in the nucleus, some are cytosolic, and 
others are capable of shuttling between the nucleus or nucleolus and the cytoplasm. It 
has been demonstrated that the methylarginine-containing domain of certain proteins is 
necessary for them to be localized to the proper subcellular compartment (Schmidt-
Zachmann and Nigg, 1993; Burgess et al., 1991; Gary and Clarke, 1998; Nichols et al., 
2000). Similarly, it has been shown in Saccharomyces cerevisiae that protein arginine 
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methylation is required for certain hnRNPs to be exported from the nucleus to the 
cytoplasm (Shen et al., 1998). 
It has long been reported that the posttranslational acetylation of certain lysine 
residues in the histones is responsible for regulating gene expression. The acetylation 
of the histones effects a change in the structure of chromatin, causing it to "loosen", 
thereby allowing the cellular machinery easier access to DNA (Pennisi, 1997; Rundlett 
et al., 1996). It has been suggested that a similar posttranslational modification, the 
methylation of arginine residues in the histone proteins, may also be at least partially 
responsible for altering the structure of chromatin (Chen et al., 1999; Hagmann, 1999). 
There have been numerous protein deacetylases identified and studied in eukaryotes; 
however, no protein arginine demethylase has yet been identified (Smith et al., 1999), 
although the existence of one has been proposed (Young and Waickus, 1987). Thus it 
appears that methylation, unlike acetylation, may be an irreversible process. Therefore, 
gene regulation through histone methylation may or may not follow the same paradigm 
as gene regulation through reversible acetylation. It should be noted, however, that the 
histones are complex proteins that are the targets of numerous epigenetic modifications 
(Hagmann, 1999); therefore, it will be difficult to determine the exact effect(s) that 
protein arginine methylation may have on these proteins, especially since these effects 
could be subtle. 
Along these same lines, there is some evidence to indicate that protein arginine 
methylation may be connected to development. In the rat, methyltransferase activity 
appears to be developmentally regulated. Protein arginine methyltransferase activity is 
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highest in fetal brain, declining steadily after birth (Paik et al., 1972 cited in Gary and 
Clarke, 1998). These results suggest a possible connection between protein arginine 
methylation and development, either in the developmentally regulated expression of 
genes or in some other aspect of growth and development. 
It has also been hypothesized that there may be a link between protein arginine 
methylation and metastasis (Gu et al., 1999; Pennisi, 1997). Elevated levels of protein 
arginine N-methyltransferase activity have been reported in highly proliferating tissues, 
and there is a correlation between the level of methyltransferase activity and the degree 
of proliferation (Rajpurohit et al., 1994b; Scorilas et al., 2000). While there are three 
mRNA transcripts of protein arginine methyltransferase 1 (Prmtl) present in normal 
mammary cells, two of these transcripts are significantly down-regulated in breast 
cancer cells (Scorilas et al., 2000). In addition, a 20 kDa protein of unknown function 
has been isolated from four different cancer cell lines and shown to be methylated at 
multiple arginine residues; however, this same protein is present but unmethylated in 
normal colon cells (Gu et al., 1999). Although not conclusive, this evidence suggests 
the involvement of protein arginine methylation in cellular proliferation and metastasis. 
The human Janus kinase binding protein 1 (JBPl) and its yeast homolog, Hsl7p, 
contain a methyltransferase motif and have been shown to exhibit protein arginine 
methyltransferase activity (Pollack et al., 1999; Lee et al., 2000). JBPl binds to Janus 
kinase (Jak), which is involved in the Jak-Stat (signal transducers and activators of 
transcription) pathway (Pollack et al., 1999). PRMTl, a mammalian protein arginine 
methyltransferase, was first identified because of its ability to interact with the 
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intracytoplasmic domain of the interferon-a,p receptor, which is also involved in the 
Jak:-Stat pathway (Abramovich et al., 1997). The Jak:-Stat pathway is involved in both 
signal transduction and cell cycle regulation, suggesting that methyltransferases may 
play a role in cell signaling and/or cell cycle regulation (Pollack et al., 1999). 
The methylation of a single arginine residue, arginine-I 07 (R-107), in the 
myelin basic protein (MBP) is critical to the function of MBP within the myelin 
membrane. It has been shown that arginine methylation is involved in maintaining the 
integrity of the myelin sheath, and the inhibition of MBP-specific methyltransferase 
activity during myelinogenesis leads to dysmyelination (Amur et al., 1986; Kim et al., 
1997b ). MBP undergoes several posttranslational modifications, all of which affect the 
charge microheterogeneity of the mature protein. These modifications, one of which is 
methylation, alter the hydrophobicity of the protein which, in turn, affects the ability of 
the MBP to interact with, and bind to, the lipids in the myelin membrane (Zand et al., 
1998; Boggs et al., 1999). Methylated MBP is less cationic than unmethylated MBP 
(Ghosh et al., 1991), and the methylation of MBP alters the thermodynamics of the 
MBP-myelin membrane association by decreasing the free energy of the protein-lipid 
interaction by 0.9 kcal/mole (Young et al., 1987). The methylarginine residue in MBP 
occurs near the N-terminus, and it has been shown in vitro that the N-terminal half of 
the MBP interacts with lipids more than the C-terminal half of the protein (Boggs et al., 
1999). Therefore, protein arginine methylation is involved in the development and 
maintenance of the mammalian central nervous system. 
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Protein arginine methylation has also been implicated in a number of 
autoimmune diseases. There has been some evidence presented to link the methylation 
of R-107 in the MBP to multiple sclerosis (MS). MS is a neurological disease 
characterized by an erosion of the myelin sheath and is believed to be caused by an 
autoimmune attack on myelin. It has been suggested that the autoantigen responsible 
for the disease is MBP itself (Moscarello et al., 1994). Once the myelin has been 
disrupted, MBP is broken down in the body and excreted in the urine (Whitaker, 1998; 
Whitaker et al., 1999). Analysis of the dimethylarginine (Me2Arg) content of MBP 
breakdown products in the urine of chronic MS sufferers confirms the presence of 20-
33 % less Me2(sym)Arg than would be expected (Rawal et al., 1995b). Since 
methylated MBP is resistant to enzymatic digestion, it has been suggested that the rate 
of MBP degradation and, therefore, the progression of the disease, may be related to the 
methylation status of the R-107 in the protein (Kim et al., 1997b). 
It has also been shown that, based on the morphology of the myelin membrane 
and the level of charge microheterogeneity in the MBP, the myelin present in MS 
patients is developmentally immature (Moscarello et al., 1994). The composition of the 
MBP in myelin changes throughout development. In the mouse and other rodents, 
where several alternatively spliced isoforms of MBP exist, the temporal expression 
pattern of each isoform is unique (Barbarese et al., 1978; Carson et al., 1983; Kruger et 
al., 1999). It has also been shown that the amount and type of MBP methylation in 
young rodent brains is different from that found in mature brains (Rawal et al., 1995a). 
MBP isolated from normal adult rat brains contains MeArg and symmetrical 
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dimethylarginine (Me2(sym)Arg). In young rat brains, however, MBP contains an 
additional isomer, asymmetrical dimethylarginine (Me2(asym)Arg), which is not found 
in adult brains (Rawal et al., 1995a). It is not clear if the immature myelin present in 
MS patients is either the cause, or the result, of the disease; in either case, the etiology 
of the disease includes demyelination, which may be linked to abnormal MBP 
methylation. 
In addition to its possible role in MS, MBP is the primary autoantigen associated 
with allergic encephalomyelitis (Eylar and Thompson, 1969). There are other 
methylarginine containing proteins that have been associated with autoimmune 
diseases, as well. Fibrillarin, which contains several methylarginine residues, was first 
identified because of its immunoreactivity to scleroderma antibodies (Ochs et al., 1985). 
Antibodies from patients with systemic lupus erythematosus have been used to identify 
three methylarginine-containing protein autoantigens involved in this disease: 
heterogeneous ribonucleoprotein Al, nucleolin, and Sm protein D1 (Minota et al., 
1991; Jensen et al., 1988; Brahms et al., 2000). On a separate, but related, note: 
peptides containing citrulline, a different posttranslational arginine modification, have 
been implicated in rheumatoid arthritis, another autoimmune disease (Schellekens et al., 
1998). Therefore, there appears to be a link between arginine modification and the 
etiology of certain autoimmune diseases. 
Protein arginine methylation is an important posttranslational modification that 
is believed to play a variety of roles in the cell and in the mammalian central nervous 
and immune systems. Proteins containing methylarginine residues are associated with 
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substrate-ligand binding, including protein-nucleic acid and protein-protein 
interactions. They are also associated with signal transduction, development, the 
regulation of gene expression and cellular proliferation, nervous system function, and 
the etiology of certain autoimmune diseases. In addition, methylarginine-containing 
domains have been shown to be necessary for the proper subcellular localization of 
many proteins. Although the precise role(s) that protein arginine methylation plays has 
yet to be definitively determined, it is clear that the processes associated with this 
modification are numerous and diverse, and necessary for proper cellular and 
organismal function. 
4. In vivo Substrates for Protein Arginine Methyltransferases 
There are several known in vivo substrates for protein argmme 
methyltransferases. Some are localized in the nucleus or nucleolus, some are cytosolic, 
and others are capable of shuttling between the nucleus/nucleolus and the cytoplasm. 
The biological function of many of these substrates is well known, while the role of 
others has yet to be elucidated. Most of the known substrates are either 
monomethylated or asymmetrically dimethylated; however, two substrates have been 
identified that contain symmetrically dimethylated arginine residues. 
A. Asymmetrically Methylated Substrates 
1. Yeast Hrp 1 p Protein 
Heterogeneous nuclear ribonuclear proteins (hnRNPs) are RNA-binding 
proteins involved in the complex process of RNA maturation. There are at least 20 
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hnRNPs in the eukaryotic nucleus, and most of these have been shown to contain 
methylarginine residues (Liu and Dreyfuss, 1995). The Saccharomyces cerevisiae 
Hrp 1 p protein is an hnRNP involved in the polyadenylation and processing of the 3' 
end of mRNAs as well as mRNA export from the nucleus. Although it is predominately 
located in the nucleus, it has been found to shuttle between the nucleus and the 
cytoplasm. Hrp 1 p contains asymmetrically dimethylated arginine residues; however, it 
has been shown that the methylation of the arginine residues has little or no effect on its 
ability to bind RNA (Valentini et al., 1999). 
2. Heterogeneous Nuclear Ribonuclear Protein Al 
The heterogeneous nuclear ribonuclear protein Al (hnRNP Al) is one of the 
most abundant of the multiple polypeptide components of the eukaryotic 40S 
ribonucleoprotein particle. It contains a unique nuclear localization signal sequence that 
also functions as a nuclear export signal. Although hnRNP Al is primarily localized in 
the nucleus, it shuttles between the nucleus and the cytoplasm via a temperature-
sensitive pathway. Therefore, it is believed that hnRNP Al is involved in shuttling 
mRNA molecules from the nucleus to the cytoplasm (Michael et al., 1995). 
Alternatively spliced transcripts for the human HNRNPAl gene can encode for at least 
two protein isoforms (Buvoli et al., 1988; Biamonti et al., 1989). The protein itself 
contains a glycine- and arginine-rich (GAR) region, with four known sites for protein 
arginine methylation near the C-terminus (Williams et al., 1985; Rajpurohit et al., 
1994b; Kim et al., 1997c ). An analysis of the modified arginine residues from this 
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region reveal both monomethylarginine and asymmetrically dimethylated argmme 
(Rajpurohit et al., 1994b ). 
3. Poly(A)-binding Protein II 
Poly(A)-binding protein II (P ABP2) is a protein that binds to the polyadenylated 
tails of nascent mRNA transcripts. Although found predominately in the nucleus, it has 
the capability to shuttle between the nucleus and the cytoplasm (Calado et al., 2000; 
Smith et al., 1999). It contains an RNA-binding domain, an acidic N-terminus, and a 
basic C-terminus containing 13 asymmetrically dimethylated and two monomethylated 
arginine residues (Nemeth et al., 1995; Smith et al., 1999). In the rat, the Pabp2 gene 
produces a 9.5-kb transcript that is expressed in brain, kidney, liver, lung, and testis 
(Muller et al., 1992). Mutations involving expansion repeats in the human PABP2 gene 
cause the autosomal dominant form of oculopharyngeal muscular dystrophy (OPMD), a 
late-onset neurological disease (Calado et al., 2000). 
4. Fibrillarin 
Fibrillarin 1s a nucleolar protein that is a part of the small nuclear 
ribonucleoprotein particle (snRNP). It is believed to be involved in processing RNA, 
specifically by shortening the preribosomal RNA from the 5' end (Aris and Blobel, 
1991). Fibrillarin contains at least six arginine residues that have been shown to be 
asymmetrically dimethylated, all of which are contained in the GAR region of the N-
terminal domain (Gary and Clarke, 1998; Aris and Blobel, 1991). Fibrillarin is present 
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in all eukaryotic species examined thus far, and fibrillarin genes have been cloned in 
Saccharomyces cerevisiae andXenopus laevis (Aris and Blobel, 1991). 
5. Nucleolin and U20 
Nucleolin, like fibrillarin, is a localized in the nucleolus. It is a phosphoprotein 
involved in the biogenesis and maturation of ribosomes (Srivastava et al., 1990). 
Unlike fibrillarin, however, nucleolin has the ability to shuttle between the cytoplasm 
and the nucleus. For this reason, it is believed that nucleolin is involved not only in the 
assembly of the ribosomes, but also in the export of pre-ribosomal particles from the 
nucleolus to the cytoplasm. The C-terminus of nucleolin contains an RGG domain, 
which has an abundance of arginine and glycine residues. This RGG domain, which 
contains asymmetrically dimethylated arginine residues, functions to modulate 
interactions between nucleolin and several ribosomal proteins (Bouvet et al., 1998). It 
is also required for proper subcellular localization (Schmidt-Zachmann and Nigg, 
1993). The nucleolin gene is well conserved across several species; it is present in 
chicken and yeast as well as in several mammalian species, where it is ubiquitously and 
constitutively expressed (Srivastava et al., 1990). The nucleolin gene is also 
responsible for producing U20, a short (80 nt) RNA transcript which, like nucleolin, is 
localized in the nucleus. U20 is immunoprecipated by antibodies to fibrillarin; 
therefore, fibrillarin and U20 may interact in vivo. U20 transcripts, which contain a 21 
nt stretch that is complementary to the sequence of the 18S rRNA, have been detected 
in all vertebrates examined so far (Nicoloso et al., 1994). 
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6. Histones 
The histone proteins are another class of proteins that have been shown to be in 
vivo substrates for protein methyltransferases (Casellas and Jeanteur, 1978). Specific 
amino acid residues on the histones can be modified by various biological processes, 
including phosphorylation, acetylation and methylation. Although the histones are 
normally methylated on lysine residues by a protein lysine methyltransferase, it has 
been shown that arginine residues on various histone proteins are substrates for protein 
arginine methyltransferases (Hagmann, 1999). Arginine residues on histones Hl, H2, 
H3, and H4 can be methylated (Frost et al., 1989; Gary and Clarke, 1998; Chen et al., 
1999; Disa et al., 1986) even though histones H2B, H2A and H3 are devoid of the GAR 
motif that has been shown to be the target of arginine methylation in other proteins. 
These non-GAR histones do, however, contain multiple arginine residues that could 
serve as methyl acceptors (Gary and Clarke, 1998). There have been conflicting reports 
about the product of protein arginine methylation in the histones; therefore, it is unclear 
if the in vivo product of this process is monomethylarginine, asymmetrically 
dimethylated arginine, symmetrically dimethylated arginine, or some combination of 
the three species (Gary and Clarke, 1998). 
7. Basic Fibroblast Growth Factor 
Basic fibroblast growth factor (bFGF), or FGF-2, is a mitogen present m 
mammalian cells (Gary and Clarke, 1998). FGF-2 is a heparin-binding protein that is 
believed to be involved in angiogenesis, osteogenesis, tissue repair, and blood pressure 
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regulation (Abraham et al., 1986; Burgess et al., 1991; Dono et al., 1998; Montero et 
al., 2000). Mice lacking Fgf-2 display a complex phenotype indicative of the 
pleiotropic nature of the protein. Although Fgf-2 null mice are viable, fertile, and 
appear morphologically normal, they display structural defects in several areas of the 
central nervous system, including the cerebral cortex, the hippocampus, and the cervical 
spinal cord. In addition, Fgf-2 deficient mice are hypotensive and have a retarded 
healing response to skin injury (Dono et al., 1998; Ortega et al., 1998). The Fgf-2 gene 
encodes multiple transcripts through alternative splicing events (Kurokawa et al., 1987). 
The high molecular weight (HMW) isoforms of the FGF-2 protein have an amino 
terminal extension containing an RGG domain with multiple sites for arginine 
methylation, and the arginine residues in this region are asymmetrically dimethylated 
(Klein et al., 2000; Gary and Clarke, 1998; Burgess et al., 1991). It has been suggested 
that this N-terminal domain, containing the methylarginine residues, is responsible for 
both the nuclear localization and the binding specificity of the HMW FGF-2 isoforms 
(Burgess et al., 1991; Plotnikov et al., 2000). 
8. ICP27 
The ICP27 protein encoded by the herpes simplex virus type 1 (HSV-1) contains 
one or more methylarginine residues in a glycine- and arginine-rich motif similar to an 
RGG box. ICP27 is an immediate-early (IE, or a.) protein that is primarily localized in 
the nucleus; however, it has been shown to shuttle between the nucleolus and the 
cytoplasm (Mears and Rice, 1996; Sandri-Goldin, 1998). ICP27 is involved in the 
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polyadenylation and splicing of RNA; it stimulates 3' RNA processmg of 
polyadenylated viral proteins while inhibiting the splicing of host mRNAs (Sandri-
Goldin, 1994). The RGG-like motif in ICP27, where the methylarginine(s) is/are 
located, is required for the protein to bind to RNA (Sandri-Goldin, 1998). Although 
this motif is not necessary for nuclear localization, it is required for the proper 
localization to the nucleolus (Mears et al., 1995). 
9. Other Proteins 
There are several other proteins that function as substrates for Type I protein 
arginine methyltransferases in vivo. Interleukin enhancer-binding factor 3 (ILF3) is a 
protein whose C-terminal is rich in glycine, arginine, and serine residues. It is a nuclear 
protein that is a substrate for, and co-immunoprecipitates with, PRMTl (Tang et al., 
2000). The yeast essential Npl3p (nucleosome assembly protein 1-like 3) protein is an 
RNA binding protein that shuttles between the nucleus and the cytoplasm. It contains 
multiple RGG motifs in its C-terminus, and evidence suggests that these C-terminal 
RGG motifs contains one or more methylarginine residues (Henry and Silver, 1996; 
Siebel and Guthrie, 1996). Sam68, a proposed adapter protein for Src kinases, contains 
a proline-rich motif flanked by a GAR domain containing asymmetrically dimethylated 
arginine residues (Bedford et al., 2000). Cytochrome c from Euglena gracilis is a 
cytosolic protein containing a single methylarginine residue near the N-terminus 
(Farooqui et al., 1985). In addition, Garl (glutamic acid-rich protein 1), Nopl 
(nucleolar protein 1), and Sbpl (skeleton binding protein 1) are all GAR-containing 
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proteins which have been shown to be methyl acceptors in vivo (Frankel and Clarke, 
1999). 
B. Symmetrically Methylated Substrates 
1. Sm Proteins D 1 and D3 
The Sm proteins D 1 and D3 are two of the numerous protein constituents of the 
spliceosome, a nuclear protein complex involved in the processing and splicing of pre-
mRNA molecules. In all eukaryotes except yeast, these proteins contain RG dipeptide 
repeats in their C-termini. These RG dipeptides, which are different from the RGG or 
GAR motifs found in other methylated substrates of PRMTs, are the site of in vivo 
arginine methylation. The human DI and D3 proteins contain nine and four arginine 
residues, respectively, in their C-terminal RG dipeptide motif, and all of these arginine 
residues exist exclusively as symmetrical dimethylarginine (Brahms et al., 2000). 
2. Myelin Basic Protein 
The myelin basic protein (MBP) is one of the major protein constituents of the 
myelin membrane. It is a highly basic protein and is the antigen responsible for allergic 
encephalomyelitis (Eylar and Thompson, 1969). In solution, the MBP molecule has 
very little secondary structure. It is considered to be highly unfolded with an open and 
extended rod-like conformation, and it is this lack of secondary structure that confers its 
unusual resistance to denaturation (Eylar and Thompson, 1969). MBP interacts in vivo 
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with acidic lipids to form the myelin sheath, and this lipid-bound state induces 
additional structural characteristics in the molecule (Lees and Brostoff, 1984). 
Although MBP exists as a single protein in humans (Carnegie, 1970 cited in 
Kim et al., 1997b ), the MBP of rodents is actually several related proteins arising from 
alternatively spliced transcripts of a single gene (deFerra et al., 1985; Takahashi et al., 
1985). There are four isoforms of MBP found in the central nervous system (CNS) 
tissue of mice, ranging in mass from 14 kDa to 21.5 kDa (deFerra et al., 1985), with 
each isoform having a unique expression pattern (Barbarese et al., 1978; Carson et al., 
1983; Kruger et al., 1999). In the mouse, MBP mRNA expression, MBP protein 
synthesis, and myelination occur synchronously (Campagnoni et al., 1978; Carson et 
al., 1983). 
The MBP gene is a part of the larger Golli (gene expressed in the 
oligodendrocyte lineage) transcription unit. The human and mouse Golli-MBP genes 
have been cloned and sequenced; they contain 10 exons, the last 7 of which encode for 
the various isoforms of MBP (Pribyl et al., 1993; Campagnoni et al., 1993). The Golli-
MBP gene maps to human chromosome 18q22-q23 (Kamholz et al, 1987); 
coincidentally, the mouse homolog maps to Mmu 18 (Sidman, 1985). The MBP gene 
contains a regulatory element located 50 nt upstream of the start of MBP transcription 
(in exon 3 of the Golli-MBP gene), and this regulatory element is required for proper 
temporal expression of the gene (Haas et al., 1995). There is also a RTS (mRNA 
transport sequence) in the 3' untranslated region where hnRNPs bind and transport the 
MBP mRNA to the distal end of the oligodendrocyte processes. Once there, it is 
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incorporated into the myelin membrane and translated into protein (Hoek et al., 1998). 
In the absence of thyroid hormone (which is involved in the regulation of 
myelinogenesis), 9-cis-retinoic acid, the ligand for the retinoic acid receptor, can 
stimulate transcription of the MBP promoter in rodent neural cell cultures (Pombo et 
al., 1999). 
MBP may serve a variety of functions in vivo. In addition to its well-
characterized role in myelinogenesis, MBP can catalyze the polymerization and 
assembly of clathrin baskets in vitro (Prasad et al., 1995). Human, bovine and rat 
MBPs have all been shown to stimulate insulin and glucagon secretion from rat 
pancreatic islets (Kolehmainen et al., 1990), and bovine MBP can inhibit the activity of 
the histone-specific PRMT (Park et al., 1989). It has also been shown that bovine 
MBP, when injected in Djungarian hamsters, causes a variety of effects in the endocrine 
pancreas, associating with, and disrupting the integrity of, the plasma and intracellular 
membranes (Kolehmainen and Sormunen, 1998). 
MBP is a highly modified protein in vivo, and these post-translational 
modifications serve to introduce charge microheterogeneity in the protein. Myelin 
isolated from CNS tissue contains any number of the following modifications: 
phosphorylated serine and threonine residues; an acetylated N-terminal residue; the 
deamidation of either a specific glutarnine residue or any of the 19 arginine residues; 
and the methylation of a single arginine residue to produce both monomethylarginine 
and symmetrically dimethylated arginine (Zand et al., 1998; Boggs et al., 1999; Young 
et al., 1987; Baldwin and Carnegie, 1971a; Deibler and Martinson, 1973; Gary and 
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Clarke, 1998). The methylation of the arginine- I 07 residue appears to be a nearly 
universal modification: with the exception of carp, it has been found in every 
mammalian and sub-mammalian vertebrate species studied (Kies et al., 1972; Deibler 
and Martenson, 1973; Young et al., 1987). 
There are several known in vivo substrates for protein arginine 
methyltransferases. These posttranslationally modified proteins are involved in a 
number of cellular processes, playing a variety of diverse roles. However, since the in 
vivo substrates of several PRMTs are unknown, there are likely to be additional 
substrates added to this list. Identification and comparison of these substrates will 
undoubtedly lead to a deeper understanding of the mechanism of the PRMT reaction 
and the role(s) that protein arginine methylation plays in the cell. 
4. Protein N-Arginine Methyltransferases (PRMTs) 
PRMT enzymes can be categorized into three subtypes: those that produce co-
N°-monomethylarginine and (asymmetric) co-N°,N°-dimethylarginine (often referred to 
as Type I); those that produce co-N°-monomethylarginine and (symmetric) co-N°,N'G_ 
dimethylarginine (Type II); and those that produce o-N°-monomethylarginine (Gary 
and Clarke, 1998; Zobel-Thropp et al., 1998; Niewmierzycka and Clarke, 1999). The 
third type of PRMT has only recently been identified and the protein is not well 
characterized (Niewmierzycka and Clarke, 1999; Zobel-Thropp et al., 1998) (Figure 
VI-1). 
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Both Type I and Type II PRMTs are stimulated by cyclic AMP and inhibited by 
S-adenosylhomocysteine ( one of the products of the methylation reaction), sinefungin 
( or adenosyl omithine, an antibiotic), adenosine dialdehyde, and catecholamines such as 
epinephrine, norepinephrine, isoproterenol (Amur et al., 1986; Najbauer et al., 1992; 
Park et al., 1989; Bussiere et al., 1998). The reactions involving these enzymes are 
highly endothermic, requiring 12 ATPs per methyl group attached, and are apparently 
irreversible (Gary and Clarke, 1998). 
A. Type I PRMTs 
There have been several Type I PRMTs identified and cloned in a wide variety 
of eukaryotic organisms. All of them contain the signature methyltransferase motifs; 
however, these enzymes can, and do, vary widely in their sequence outside these 
regions. There are only three PRMTs known so far in yeast, all of which have 
homologs in other eukaryotes. There are five PRMTs cloned so far in mammals, and it 
is possible that there are others that have not yet been identified. 
1. Yeast Type I PRMTs 
There have been two Type I methyltransferases identified from Saccharomyces 
cerevisiae: RMTl (protein arginine methyltransferase 1) and RRP8. RMTl, which has 
also been called HMTl (hnRNP methyltransferase 1), was identified by its homology to 
the rat PRMTl gene (Gary et al., 1996; Gary and Clarke, 1998). RMTl contains four 
conserved methyltransferase motifs: I, post I, II, and ill (Gary et al., 1996). It is a 
nuclear protein that can methylate a number of substrates in vivo, including NPL3 
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(nucleosome assembly protein I-like 3), a yeast hnRNP. RMTl, unlike its NPL3 
substrate, is not essential for cell viability (Henry and Silver, 1996). Crystallographic 
evidence suggests that RMTl is oligomeric, existing as a hexamer in solution (Weiss et 
al., 2000). Sequence analysis of the Rmtl gene reveals two regions of similarity to 
other protein arginine methyltransferases: a stretch of 63 nucleotides showing strong 
similarity to the SAM-binding motif of other methyltransferases, and a stretch of 48 
nucleotides containing a nuclear localization signal (Henry and Silver, 1996). 
RRP8 is another methyltransferase identified from Saccharomyces cerevisiae. It 
is a nucleolar protein involved in pre-rRNA cleavage. Database searches indicate that 
the C-terminal domain of RRP8 shows homology to proteins from a variety of 
organisms, including Arabidopsis thaliana, Caenorhabditis elegans, Plasmodium 
falciparum, Schizosaccharomyces pombe, and mammalian species as well (Bousquet-
Antonelli et al., 2000). RRP8 was first reported to contain only one signature 
methyltransferase domain (Niewmierzycka and Clarke, 1999); however, further analysis . 
confirms that it contains four conserved methyltransferase domains: I, post I, II, and ill 
(Bousquet-Antonelli et al., 2000). 
2. Mammalian Type I PRMTs 
a. Protein arginine methyltransferase 1 
Protein arginine methyltransferase 1 (PRMT 1) is the first mammalian PRMT to 
be identified and cloned, and is responsible for the majority of PRMT enzyme activity 
found in mammals (Lin et al., 1996; Tang et al., 2000). It was recovered using a yeast 
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two-hybrid assay to identify proteins interacting with two similar proteins: TIS21, an 
immediate-early protein of unknown function, and BTG 1, an antiproliferative protein 
involved in chronic lymphocytic leukemia (Lin et al., 1996). PRMTl was later 
identified as a ligand for the Interleukin enhancer-binding factor 3 (ILF3), and has been 
shown to methylate the C-terminus of1LF3 in vitro (Tang et al., 2000). It has also been 
shown to interact with both the intracytoplasmic domain of the interferon-a,13 receptor 
and the C-terminal AD2 activation domain of p 160 family of coactivators (Abramovich 
et al., 1997; Koh et al., 2001). 
PRMTl is classified as a type I protein arginine N-methyltransferase because of 
its ability to form monomethyl- and asymmetrical dimethylarginine residues (Gary and 
Clarke, 1998). The in vitro activity of PRMTl is strongly inhibited in the presence of 
Tris and arginine but is unaffected by citrulline (a deamidated arginine), or the steroid 
hormones (Frankel and Clarke, 2000; Scorilas et al., 2000). Conversely, ILF3 has been 
shown to enhance the activity of PRMTl in vitro (Tang et al., 2000). Native PRMTl 
can methylate the histones, hnRNP Al, and the poly(A)-binding protein II (PABP2) 
(Lin et al., 1996; Smith et al., 1999). A Glutathione S-transferase (GST) fusion protein 
containing the catalytic portion of PRMTl has been shown to methylate GST-GAR, an 
artificial substrate containing GST fused to the glycine- and arginine-rich amino-
terminal residues of fibrillarin (Tang et al., 1998). However, the GST-PRMTl protein 
is unable to methylate either cytochrome c or the myelin basic protein (Lin et al., 1996; 
Smith et al., 1999). 
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PRMTl contains four highly conserved methyltransferase motifs: I, post I, II, 
and ill (Lin et al., 1996). It is interesting to note, however, that PRMTl contains few 
residues other than those identified in the conserved motifs (Frankel and Clarke, 1999). 
PRMTl is an oligomeric protein, with reports of dimers and hexamers forming in 
solution (Tang et al., 1998; Weiss et al., 2000). Although the exact function of the 
PRMTl oligomers is unknown, it has been shown that dimerization is essential for 
catalytic activity (Weiss et al., 2000). 
The PRMTl gene contains 12 coding exons and spans an 11.2-kb genomic 
interval (Scorilas et al., 2000). It maps to human chromosome 19q13.3 (Scott et al., 
1998; Scorilas et al., 2000). In the mouse it maps to chromosome 7, proximal to Ldh3, 
Gas2, Snrpn, and Ube3a (Pawlak et al., 2000). This places Prmtl just proximal to the 
p-deletion complex. There are no human disease phenotypes or mouse mutations 
known to map near these regions of the human or mouse genomes (Pawlak et al., 2000). 
Prmtl produces a primary 1.282-kb mRNA transcript in the mouse (Pawlak et 
al., 2000); however, at least two alternatively spliced transcripts, differing at their 5' 
ends, have been detected (Scott et al., 1998; Scorilas et al., 2000). Prmtl is 
ubiquitously expressed in both rodent and human tissues (Lin et al., 1996; Scott et al., 
1998). Cell culture studies indicate that its activity is not required for cell viability; 
however, Prmtl is constitutively expressed in mitogen-stimulated cells and is necessary 
for early embryonic development in the mouse (Lin et al., 1996; Pawlak et al., 2000). 
While all three mRNA transcripts of Prmtl are present in normal mammary cells, two 
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of the transcripts have been shown to be significantly down-regulated in breast cancer 
cells (Scorilas et al., 2000). 
Of all the known mammalian protein arginine methyltransferase genes, only one 
mutation, arising from a targeted retroviral insertion in the mouse prmtl gene, has been 
described. This prmtl mutation is essentially a null mutation, producing mRNA 
transcript levels of only 1 %, compared to the wild-type. The prmtl knockout is 
embryonic lethal, with death occurring at around day E6.5. Although the prmtl null 
mutation is an embryonic lethal and PRMTl is responsible for the major proportion of 
methyltransferase activity in cells, it has been shown that PRMTl activity is not 
required for viability in mouse ES cells (Pawlak et al., 2000). 
b. Protein arginine methyltransferase 2 
The human PRMT2 gene was identified because of its similarity to the rat 
PRMTl gene. It maps to human chromosome 21q22.3 (Scott et al., 1998; Katsanis et 
al., 1997), and contains five conserved methyltransferase domains: I, post I, II, III, and 
post III. It also contains a Src homology 3 (SH3) domain in its 5' end, making it unique 
among all other previously identified members of the protein arginine methyltransferase 
family (Katsanis et al., 1997). This SH3 domain is involved in protein-protein binding, 
and methylarginine residues present in the protein substrate serve to reduce the level of 
interaction between the SH3-containing ligand and its (methylarginine-containing) 
substrate (Bedford et al., 2000). The Prmt2 gene encodes a 2.8-kb mRNA that is 
ubiquitously expressed, with slightly higher levels of expression in brain and placenta 
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and lower levels in the liver and lung. There is some evidence to suggest that a larger 
transcript may be present in breast and fetal heart, but this has not been conclusively 
determined (Katsanis et al., 1997). It is interesting to note, however, that despite the 
homology between PRMT2 and other protein arginine methyltransferase family 
members, the PRMT2 protein has not been shown to have protein arginine 
methyltransferase activity (Scott et al., 1998). Therefore, PRMT2 may be a structural, 
but not functional, member of the PRMT family. 
c. Protein arginine methyltransferase 3 
Protein arginine methyltransferase 3 (PRMT3) is a type I protein arginine N-
methyltransferase that was recovered using a yeast two-hybrid assay to identify proteins 
interacting with PRMTl, the first mammalian PRMT to be identified and cloned. The 
PRMTl and PRMT3 proteins are 67% similar and 46% identical at the amino acid level 
over the methyltransferase domain in their carboxy-terminal region; however, their 
amino-terminal ends are dissimilar. The N-terminus of PRMT3, which contains an 
abundance of acidic residues, is called the N-terminal acidic amino acid-rich (NAR) 
domain. This NAR domain, which contains both a C2H2 zinc finger motif and a 
tyrosine phosphorylation consensus sequence, shows no significant homology to other 
known proteins (Tang et al., 1998). 
The in vivo substrate for PRMT3 1s unknown; however, a glutathione S-
transferase (GST) fusion protein containing the catalytic portion of PRMT3 has been 
shown to methylate GST-GAR, an artificial substrate containing GST fused to the 
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glycine- and arginine-rich amino-terminal residues of fibrillarin, which has multiple 
arginine residues that serve as targets for methylation (Tang et al., 1998). PRMT3 and 
PRMTl have both been shown to methylate arginine residues in the C-terminal domain 
of poly(A)-binding protein II (P ABP2), a protein believed to be involved in pre-mRNA 
polyadenylation, in a methylation pattern consistent with the natural methylation of 
PABP2 (Smith et al., 1999). The activity of PRMT3, unlike that of PRMTl, is 
relatively unaffected by the addition of Tris to the in vitro reaction mixture; however, 
both enzymes are inhibited by arginine, and both are unaffected by the addition of 
citrulline, the posttranslationally deamidated adduct of arginine (Frankel and Clarke, 
2000). In addition, there is a single 29 kDa substrate present in hypomethylated yeast 
rmtl extracts that is methylated by GST-PRMT3, but not GST-PRMTl (Tang et al., 
1998). 
PRMT3 is the only known enzyme with protein arginine N-methyltransferase 
activity to have a zinc finger motif. PRMT3 binds zinc in a 1: 1 stoichiometric ratio, and 
it is this zinc finger domain of PRMT3 that appears to be responsible for conferring 
substrate specificity (Frankel and Clarke, 2000). GST-PRMT3 fusion proteins 
containing only the catalytic portion of PRMT3 (without the zinc finger domain) will 
methylate GST-GAR; however, it was found that the zinc-chelated form of PRMT3 was 
required for the enzyme to recognize certain RNA-associated substrates in RATl cell 
extracts (Frankel and Clarke, 2000). This is consistent with the notion that zinc fingers 
are involved in protein-ligand binding, including protein-DNA, protein-RNA, and 
protein-protein interactions (Mackay and Crossley, 1998). 
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The Prmt3 gene produces a 2.4-kb mRNA transcript m the rat, which 1s 
constitutively and ubiquitously expressed except in liver, where no expression 1s 
detected via Northern blotting. Immunolocalization studies indicate that PRMT3 is 
cytoplasmic, while PRMTl is localized in the nucleus. Although yeast two-hybrid data 
indicate that PRMT3 has the potential to form homo-oligomers as well as hetero-
oligomers with PRMTl, gel filtration analysis indicates that PRMT3 is monomeric 
(Tang et al., 1998). Crystallographic evidence, however, indicates that the PRMT3 core 
forms a homo-dimer when crystallized in the presence of a cofactor (S-
adenosylhomocysteine ). These homo-dimers, and perhaps even PRMT1/PRMT3 
hetero-dimers, may also be present in equilibrium with the monomers in vivo (Zhang et 
al., 2000), but are unable to survive the process of cell disruption and gel filtration 
analysis (Tang et al., 1998), possibly due to the thermodynamics of the 
association/dissociation. 
d. Protein argmme methyltransferase 4 / Coactivator-associated argmme 
methyltransferase 1 
Protein arginine methyltransferase 4 (PRMT4), or Coactivator-associated 
arginine methyltransferase 1 (CARMI), is a protein that associates with the p160 family 
of coactivators, which are nuclear hormone regulated transcription factors. In the 
mouse, CARMI is expressed as a 3.8-kb mRNA transcript in a wide variety of tissues. 
It shows 30 percent identity at the amino acid level to human PRMTl, and has been 
shown to preferentially methylate histone H3. CARMI regulates transcription by 
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binding to the C-terminus of these p160 coactivators, in the AD2 activation domain. 
Mutations affecting the ability of CARMl to bind S-adenosylmethionine have been 
shown to significantly reduce both its methyltransferase and coactivator activities (Chen 
et al., 1999; Chen et al., 2000; Stallcup et al., 2000). 
e. Protein arginine methyltransferase 5 I Janus kinase binding protein 1 
Protein arginine methyltransferase 5 (PRMT5) is a cytoplasmic, homo-
oligomeric protein that was originally called Janus kinase binding protein 1 (JBPl) 
(Frankel and Clarke, 2000; Rho et al., 2001). The human JBPl and its yeast homolog, 
Hsl7p, contain a methyltransferase motif and have been shown to exhibit protein 
arginine methyltransferase activity (Pollack et al., 1999; Lee et al., 2000). JBPl binds 
to Janus kinase (Jak), which is involved in the Jak-Stat (signal transducers and 
activators of transcription) pathway (Pollack et al., 1999). Yeast two-hybrid analysis 
indicates that it also interacts with the nonstructural protein 3 encoded by the hepatitis C 
virus (Rho et al., 2001). Although the in vivo substrate for the methyltransferase 
activity of JBPl has not been identified, a GST-PRMT5 fusion protein has been shown 
to methylate various Type I artificial substrates as well as MBP, a Type II substrate. It 
has not been determined, however, if the dimethylation pattern of MBP methylated by 
PRMT5 is symmetrical or asymmetrical; therefore, it is not clear if PRMT5 functions as 
a Type I, Type II, or a Type I/II enzyme (Rho et al., 2001). The Jak-Stat pathway is 
involved in both signal transduction and cell cycle regulation; therefore, the 
involvement of a methyltransferase in this pathway suggests that protein arginine 
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methylation may play a role in cell signaling and/or cell cycle regulation (Pollack et al., 
1999). 
B. Type II PRMTs 
Since the discovery, 30 years ago, of the methylation of a specific arginine 
residue in the myelin basic protein (Baldwin and Carnegie, 1971b; Brostoff and Eylar, 
1971) and the further identification of the modified residue as symmetrically 
dimethylated arginine (Diebler and Martenson, 1973), scientists have been searching for 
the enzyme responsible for this posttranslational modification. The enzymatic activity 
of the MBP-specific PRMT has been isolated (Crang and Jacobson, 1982; Sundarraj 
and Pfeiffer, 1973) and this enzyme activity is different from the activity of the histone-
methylating PRMT (Kim et al., 1997b ). However, a single protein representing this 
activity has yet to be purified (Gary and Clarke, 1998). 
The proposed kinetic mechanism for the enzyme involves AdoMet binding to 
the enzyme first, followed by rapid-equilibrium binding to the substrate (Young and 
Waickus, 1988). Studies of the Type II PRMT activity indicate that the preferred 
sequence for methylation is an arginine flanked on either side by glycines, although the 
enzyme retains at least partial activity when the N-terminal flanking glycine is 
substituted by certain amino acids (Hyun et al., 2000). It was found that the MBP-
specific PRMT requires a substrate of at least six residues for minimal activity, and that 
methyltransferase activity increases as the length of the substrate peptide increases 
(Ghosh et al., 1991; Hyun et al., 2000). 
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In addition to the standard inhibitors of all PRMTs, the MBP-specific PRMT is 
regulated by thyroid hormone and nitrous oxide (Amur et al., 1984; Amur et al., 1986). 
It is interesting to point out that animals exposed to nitrous oxide for prolonged periods 
of time show neurological effects due to demyelination (Amur et al., 1986). In the 
mouse, it has been shown that the activity of this methyltransferase is synchronized with 
myelination (Crang and Jacobson, 1982; Kim et al., 1988; Rawal et al., 1991), and 
inhibition of the MBP-specific PRMT leads to incomplete myelination (Amur et al., 
1986). 
C. Other PRMTs 
RMT2 is a umque methyltransferase that was identified through analyzing 
SAM-binding sequence motifs found within the Saccharomyces cerevisiae genome. It 
is considered unique because it can methylate the a-nitrogen of protein arginine residues 
(Niewmierzycka and Clarke, 1999), a modification that was only recently described 
(Zobel-Thropp et al., 1998). RMT2 contains the conserved methyltransferase motifs I, 
post I, II, and ill, and it shares significant identity to the human guanidinoacetate N-
methyltransferase enzyme, which methylates the a-nitrogen atom in guanidinoacetate. 
RMT2 homologs have been identified in Schizosaccharomyces pombe and Arabidopsis 
thaliana, but not in higher eukaryotes or prokaryotes. In yeast, RMT2 is essential for 
neither viability nor growth. Although the methyl-accepting substrate(s) for RMT2 has 
not been identified, it is believed that the substrates are fully methylated and that 
methylation occurs on the nascent proteins (Niewmierzycka and Clarke, 1999). 
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CHAPTER VII 
SEQUENCE AND EXPRESSION ANALYSES OF CANDIDATE GENES 
ABSTRACT 
Sequence analysis of B 179d 14 identified two candidate genes for the psrt 
phenoypte: Tip30/Cc3 and Prmt3. The Tip30/Cc3 and Prmt3 mRNAs are ubiquitously 
and constitutively expressed. Sequence analysis of the Tip30/Cc3 cDNA indicates that 
the sequence is identical in the control and the two mutant strains, 723SJ and 1060SJ. 
There is evidence to suggest, however, that the Prmt3 gene is altered in the mutants. 
Sequencing of cloned RT-PCR products failed to find a mutation in the 1060SJ Prmt3 
cDNA, but temperature-gradient capillary electrophoresis (TGCE) mediated 
heteroduplex analysis strongly indicates that a mutation is present in the 3' end of the 
transcript. Sequencing of the 723SJ Prmt3 cDNA also failed to find a mutation; 
however, the 5' end of the 723SJ allele could not be amplified, either through standard 
RT-PCR or through 5' RACE. Southern blot analysis failed to verify a genomic 
rearrangement or deletion. However, TGCE heteroduplex analysis also indicates a 
mutation is present in the 3' end of the 723SJ transcript. 
INTRODUCTION 
In order to evaluate the candidacy of the two genes identified through sequence 
analysis of BAC B 179d 14, an expression analysis of each of the genes was performed 
in the mutant and control animals. The tissue-specific and temporal mRNA expression 
80 
patterns, as well as the cDNA sequence, will be useful in determining whether either of 
these genes could be responsible for the psrt phenotype. 
MATERIALS AND METHODS 
1. RNA Isolation 
Total RNAs from brain were isolated using standard methods (Chirgwin et al., 
1979, Sambrook et al., 1989). Poly (At RNAs were isolated from total RNAs using 
the Mini-Oligo (dT) Cellulose Spin Column Kit (5 Prime 3 Prime, Inc., Boulder, CO) 
following the manufacturer's instructions. 
2. RT-PCR 
Approximately 5µ,g of total RNA were reverse transcribed in a 20 µ,L reaction 
volume using Superscript II (Gibco BRL Life Technologies, Rockville, MD). A variety 
of primer combinations were used to amplify the cDNAs from both the Prmt3 and the 
Tip30/Cc3 genes (Table VII-1). Actin-specific primers (ORN 559/560) were used to 
amplify a 520 bp fragment of /3-actin as the internal control (Alonso et al., 1986). 
3. Northern Blots 
Total RNAs were run on a 1 % denaturing formaldehyde agarose gel and 
electrophoresed in lX MOPS buffer (Sambrook et al., 1989). After electrophoresis, the 
gels were soaked for 30 minutes in 50 mM NaOH, rinsed in DEPC-treated water, 
neutralized two times for 15 minutes each in 0.1 M Tris-HCl, and blotted to Duralon 
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nylon membranes overnight in 20X SSC. After the transfer was complete, the blots 
were dried under vacuum at 80°C for two hours, and UV crosslinked at 250 
mjoules/mm 2 in a Stratalinker (Stratagene, LaJolla, CA) before prehybridization. 
4. RACE 
5' RACE was performed using the Clontech SMART™ RACE Kit (Clontech, 
Inc.; Palo Alto, CA) according to the manufacturer's instructions. RACE was 
performed on first strand cDNAs generated from both poly (At RNAs and total RNAs 
from brain using both standard and touchdown PCR programs. Primers for the reaction 
were ORN 645 and ORN772, used with the universal primer and nested universal 
primer supplied with the RACE kit (Table VII-I). 
5. MTC Panels 
The mouse MTC (multiple tissue cDNA) panel (Clonetech, Inc.; Palo Alto, CA) 
was used to analyze, by PCR, expression of the candidate genes in different mouse 
tissues. This panel includes cDNAs from heart, brain, spleen, lung, liver, skeletal 
muscle, kidney, testis, and four different embryo stages (7-, 11-, 15-, and 17-day). The 
Prmt3 PCRs utilized primers ORN 646 and 648, which amplify a 586 hp fragment from 
the 3' end of the transcript. The Tip30/Cc3 PCRs utilized primers ORN 663 and 664, 
which amplify a 1060 hp fragment covering the entire coding sequence of the transcript. 
Actin-specific primers (ORN 559/560) were m~ed to amplify a 520 hp fragment of /3-
actin as an internal control (Alonso et al., 1986). For PCR, the conditions were 94° for 
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5 min, followed by 30 cycles of 94° for 30 sec, 1 min at the appropriate annealing 
temperature (60°C for ORN 663/664, 52°C for ORN 559/560, and at 62°C for ORN 
646/648), and 72° for 3 min., then a final five minute extension at 72°C. Products were 
analyzed on a 1 % agarose gel with ethidium bromide staining (Sambrook et al., 1989). 
6. Cloning and Sequencing RT-PCR Products 
The PCR products obtained were cloned using the pGEMT-Easy II cloning kit 
(Promega Corporation, Madison, WI), following the manufacturer's instructions, and 
analyzed by fluorescent sequencing with the Big Dye Terminator Kit (PE Biosystems, 
Foster City, CA). The products were run on an ABI377 DNA sequencer and the 
sequence analyzed using BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) to verify the 
identity of the cloned products. 
7. Assembling cDNA Sequences 
Individual sequencing runs from the RT-PCR products were assembled into 
contigs representing the entire cDNAs using the Sequencher 3.1 software (Gene Codes 
Corp., Ann Arbor, Ml). 
8. Mutation Screening by Temperature-Gradient 
Capillary Electrophoresis 
RT-PCR amplified fragments of the Prmt3 cDNA from the control (BJR) and 
the two mutant strains (723SJ and 1060SJ) were analyzed for mutations using 
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temperature-gradient capillary electrophoresis (TGCE) (Gao and Yeung, 2000). Six 
overlapping fragments were analyzed, ranging in length from 204 bp to 530 bp (Figure 
VIl-2). The analysis was performed by SpectruMedix Corporation (State College, PA), 
in collaboration with Cymbeline T. Culiat of ORNL. 
9. Genomic Southern Blotting 
Genomic DNAs from 723SJ and 1060SJ psrt mutants and the BJR control were 
digested overnight with BstXI., EcoRI, Pstl, and Taql (Gibco BRL Life Technologies, 
Rockville, MD) using the following reaction cocktail: 1 Oµg of miniprep DNA, 4 µL of 
10 X buffer (React2 for with Pstl and Taql, and React3 for BstXI. and EcoRI), 2 µL of 
enzyme, and sterile water to make a total volume of 41 µL. Digestions occurred 
overnight at 37°C except those using Taql, which were digested at 65°C. Digested 
DNAs were loaded on a 0.8% agarose gel which was run in IX TAE and Southern 
blotted using standard protocols (Sambrook et al., 1989). 
RESULTS 
1. Tip30/Cc3 cDNA Sequence 
The Tip30/Cc3 cDNA was amplified using primers ORN 663 and ORN 664, 
which amplify a 1060 bp fragment that includes the entire coding sequence of the 
Tip30/Cc3 cDNA. Three sets of primers were also used to amplify smaller, overlapping 
segments of the cDNA: ORN 663 and ORN 728, which amplify a 615 bp segment in 
the 5' end of the cDNA; ORN 664 and ORN 727, which amplify a 464 bp segment in 
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the 3' end of the cDNA; and ORN 723 and ORN 726, which amplify a 560 hp segment 
in the middle of the cDNA that overlaps the other two segments (Figure VII-3). 
The consensus sequence was determined by combining all sequencing data, 
including data from both the cloned RT-PCR fragments and from the direct sequencing 
of RT-PCR products. No point mutations or other discrepancies in the sequence were 
found between the control (BJR) strain and the two mutant strains (723SJ and 1060SJ). 
2. Tip30/Cc3 Expression Analysis 
Primers ORN 663 and ORN 664 were used to look for expression in tissues 
from the Mouse MTC panel. A single 1060 hp fragment was detected for all twelve 
cDNAs tested (Figure VII-4), indicating that Tip30/Cc3 is ubiquitously expressed in 
mouse adult and embryonic tissues. 
3. Prmt3 cDNA Sequence 
The Prmt3 cDNA was amplified from the two mutant strains and the control 
using two sets of primers that amplify overlapping segments of the cDNA: ORN 646 
and ORN 648, which amplifies a 586 hp segment in the 3' end of the cDNA that 
includes the stop codon and part of the 3' UTR; and ORN 644 and ORN 647, which 
amplify a 685 hp segment in the middle of the cDNA that overlaps the other two 
segments (Figure VII-5). No amplification product could be obtained from the 723SJ 
psrt cDNA using ORN 645 and ORN 704, which amplify a 569 hp segment in the 5' 
end of the cDNA that includes the start codon and a short segment of the 5' untranslated 
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region (UTR). There was, however, an amplification product from the 1060SJ mutant 
and the BJR control cDNAs. 
When visualized on an ethidium bromide stained agarose gel, the ORN 644/647 
product amplified from 1060SJ mutants appears to be a single product; however, during 
the process of cloning and sequencing, a single clone was isolated that carries an 
alternatively spliced insert. This anomalous clone is missing hp 844 to 1063, which 
corresponds to exons nine and ten. Therefore, although this transcript is in low 
abundance, at least one alternatively spliced transcript exists for the Prmt3 gene in the 
1060SJ animals. 
The Prmt3 consensus sequence was determined by combining all sequencing 
data, including data from both the cloned RT-PCR fragments as well as from the direct 
sequencing of RT-PCR products. No point mutations or other discrepancies in the 
sequence were found between the control (BJR) strain and the two mutant strains 
(723SJ and 1060SJ). 
4. 5' RACE 
RACE was utilized in an attempt to amplify the 5' end of the 723SJ Prmt3 
cDNA, which could not be amplified by standard RT-PCR. The RACE controls were 
successfully amplified; however, repeated attempts at amplification of the 723SJ cDNA 
using both total RNAs and poly (At RNAs were unsuccessful. These results suggest 
the presence of a possible genomic rearrangement or deletion in the 723SJ Prmt3 allele. 
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5. Prmt3 Expression Analysis 
Primers ORN 646 and ORN 648 were used to look for expression in tissues 
from the Mouse MTC panel. A 586 bp fragment was detected for all twelve cDNAs 
tested, and a second, larger fragment was also detected in skeletal muscle and possibly 
in heart (Figure VII-6). This indicates that Prmt3 is ubiquitously expressed in mouse 
adult and embryonic tissues, and that at least one larger, alternatively spliced transcript 
is present in skeletal muscle and heart. 
Northern blot analysis of brain total RNA probed with a Prmt3 EST (Genbank 
Accession #ai 156519) indicates that the Prmt3 transcript is approximately 2.4-kb, 
which agrees with the size previously reported for rat brain {Tang et al., 1998). The 
723SJ psrt transcript appears to be slightly shorter than the 1060SJ psrt transcript and 
the controls (Figure VII-7). However, this difference is slight, at best, and has not been 
quantified. 
6. Detection of Genomic Rearrangement or Deletion 
The genomic Southern blot of DNAs from the control strain (BJR) and the two 
mutant strains (723SJ and 1060SJ) was probed with RT 645/704, a RT-PCR product 
from the 5' end of the Prmt3 cDNA transcript. The enzymes used to digest the genomic 
DNA were chosen because the genomic sequence ( obtained from the BAC containing 
the Prmt3 and Tip30/Cc3 genes, B179d14) indicates the presence of restriction sites for 
each of the enzymes within the first 20-kb of the Prmt3 gene and the 5-kb of genomic 
sequence directly upstream of the gene. In addition, the restriction map of all four 
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enzymes shows an abundance of fragments ranging from 0.3-kb to 6-kb, which could be 
detected on a Southern blot (Table VII-8). If either a genomic rearrangement or deletion 
were present in one of the mutant strains, then the size of the band(s) might be altered 
relative to the other strains. The autoradiograph of the probed blot, however, showed 
identical bands for the three DNAs, each digested with four different enzymes. This 
indicates that, for the four enzymes used, no deletion or rearrangement is detected 
(Figure VII-9). 
7. Prmt3 TGCE Mutation Analysis 
A TGCE analysis is performed by mixing the amplified cDNA from a 
homozygous (or hemizygous) mutant with that from the control animal. The samples 
are then denatured and allowed to reanneal. If both the mutant and control strands are 
identical, then a homoduplex is formed and the electropherogram shows a single, 
smooth peak. However, if mutations are present, including single nucleotide 
polymorphisms (SNPs), then both heteroduplexes and homoduplexes will form when 
the samples reanneal. Since heteroduplexes and homoduplexes have different 
electrophoretic mobilities m the electrophoresis matrix [in this case, a 
poly(vinylpyrrolidone) solution], the shape of the resulting electropherogram will no 
longer be a single, smooth peak. Rather, it can range from a single peak with a 
"shoulder" to a multiplet of up to four individual peaks representing two 
complementing homoduplexes and both possible heteroduplexes. 
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The TGCE analysis performed by the SpectruMedix Corporation indicates that 
mutations are present in both of the mutant strains. Heteroduplex formation occurred in 
the 1060SJ cDNA amplified with ORN 648/676, which is from the 3' end of the cDNA 
(Figures VII-10 and VII-11). The overlapping segment, ORN 646/677, does not form 
heteroduplexes; therefore, there appears to be a mutation somewhere in the 162 bp of 
the fragment that does not overlap with ORN 646/677. The heteroduplex was detected 
in both of the two independently generated cDNAs from 1060SJ mutants that were 
analyzed. 
In addition, heteroduplex formation was also detected in the 723SJ cDNA in two 
overlapping segments, ORN 646/677 and ORN 648/676 (Figures VII-10 and VII-11). 
These two segments represent the 3' end of the cDNA; however, since both segments 
form heteroduplexes, the mutation is most probably located in the 89 bp that form the 
overlap between the two segments. The heteroduplex was detected in a single 723SJ 
cDNA (rather than in both cDNAs) because one of the two submitted samples failed to 
produce a signal. The single 723SJ cDNA did, however, show heteroduplex formation 
with both of the control samples. 
DISCUSSION 
The Tip30/Cc3 gene appears to be intact and the sequence is identical in the 
control strain and in psrt homozygotes animals from the two mutant strains. Although a 
sequence analysis using a cDNA-based primer set indicates that the Prmt3 cDNA 
sequence is unchanged between the control and the two mutant strains, there is evidence 
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to suggest that the Prmt3 gene is altered in the mutants. Northern blot analysis suggests 
a possibly shortened transcript in the 723SJ mutants, and the 5' end of the 723SJ 
transcript could not be amplified, either by standard RT-PCR or by RACE. A genomic 
rearrangement or deletion could be the cause of the problem; however, Southern blot 
data failed to verify a genomic alteration. TGCE data strongly indicate that mutations 
are present in the Prmt3 transcripts from each of the two mutant strains, both in the 3' 
end of the transcripts, with the 723SJ mutation occurring in a position more 5' than the 
1060SJ mutation. Additional sequence analysis will be required to verify these 
mutations as well as to ascertain conclusively if there is an aberration in the 5' end of 
the 723SJ transcript. 
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CHAPTER VIII 
ANALYSIS OF METHYLARGININE IN THE MYELIN BASIC PROTEIN 
OF psrt MUTANT ANIMALS 
ABSTRACT 
To assess the methylation status of the arginine-107 (R-107) residue of the 
myelin basic protein (MBP), MBP was extracted from psrt mutant and non-mutant 
mouse brains. The MBP was hydrolyzed and the amino acids derivatized with N-
methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide {MTBSTF A) to produce tert-
butyldimethylsilyl (t-BDMS) derivatives. The derivatized amino acids were analyzed 
by gas chromatography with mass spectrometric detection (GC/MS) to determine the 
methylation status of the arginine residues in MBP. The hydrolysate from the control 
animals contained the expected methylarginine residue at quantifiable levels, while the 
hydrolysate from the psrt mutants contained no detectable methylarginine. 
INTRODUCTION 
One of the candidate genes for the psrt phenotype is a protein arginine N-
methyltransferase, Prmt3, whose specific in vivo substrate is unknown. Although there 
are several proteins known to contain methylarginine residues, the myelin basic protein 
(MBP) is the only known methylarginine (Me-R)-containing protein that is involved in 
neurological function. MBP contains a single Me-R residue, arginine-107 (R-107), that 
can be either monomethylated or symmetrically dimethylated. 
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If Prmt3 is the gene responsible for psrt, then the mutants will exhibit abnormal 
protein arginine methylation. Furthermore, if MBP is the substrate for Prmt3, then 
abnormal methylation patterns would be present in the MBP isolated from the mutants. 
To investigate this possibility, MBP from the brains of the psrt mutants and their non-
psrt littermate controls were analyzed for the presence of methylargine (Me-R). 
MATERIALS AND METHODS 
1. Isolation ofMBP 
MBP was extracted from two groups of 14 day old brains: seven pooled psrt 
brains, totaling 2.08 grams, and seven pooled control brains, totaling 2.61 grams. The 
pooled mutant sample class included five 1060SJ psrt homozygotes (genotype ru2 mp I 
ru2 mp) and two hemizygotes (genotype ru2 mp I Dj[ru2-p]); the pooled 1060SJ 
control animals included five wild-type animals (genotype ru2 + + I + + p) and two 
non-carrier ru2 animals (genotype ru2 + + I ru2 + + ). MBP was isolated using a 
variation of the technique developed by Maatta et al. (1997). Briefly, the brains are 
homogenized in chloroform (99.9%, spectrophotometric grade, ACS reagent; Burdick 
and Jackson Laboratories, Inc., Muskegon, Ml) and the homogenate is centrifuged to 
isolate the MBP-containing organic phase from the pellet and the aqueous phase. The 
pellet is re-homogenized in chloroform and the process is repeated. The organic phases 
are combined, washed in water ('Baker Analyzed'® HPLC reagent; J.T. Baker, 
Phillipsburg, NJ) and centrifuged again. The MBP-containing organic phase is 
removed, mixed with ('Baker Analyzed'® HPLC reagent) methanol (J.T. Baker, 
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Phillipsburg, NJ) and vortexed. Acidified water (containing HCl) is added, and the 
mixture is vortexed again. At this stage, the MBP is dissolved in the acidic aqueous 
phase, which is removed and dried in a rotary evaporator. 
2. Hydrolysis and Derivatization of MBP 
The dehydrated MBP, which is a filmy residue in the bottom of the round 
bottom flask, is dissolved in 500 µL of 6M constant-boiling HCL (Pierce Chemical Co., 
Rockford, IL) and transferred to a hydrolysis tube. The hydrolysis is carried out 
overnight at 110°C to 120°C under vacuum. The hydrolysate is dried by warming to 
55°C under a stream of nitrogen, then derivatized at 80°C for one hour using 30 µL of 
MTBSTF A + 1 % TBDMCS (tert-butyldimethylchlorosilane, a catalyst) (Pierce 
Chemical Co., Rockford, IL) and 30 µL of pyridine (99.8%, anhydrous; Sigma, Inc., St. 
Louis, MO). 
3. GC/MS Analysis 
Samples were analyzed using a Hewlett-Packard model 5890 gas chromatograph 
with a HP-5MS capillary column (30m x 0.25mm i.d.; 0.25 µm film thickness). The 
detector was a model 5989A quadrupole mass spectrometer operating in electron impact 
ionization mode. The ion source was maintained at 70 eV and 200°C. The carrier gas 
was helium and the column head pressure was 7 psi. The injector temperature was 
250°C and the temperature program was as follows: 60°C for two minutes, then ramp 
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at 5°C per minute for 44 minutes to 280°C and hold for five minutes. The total run lasts 
51 minutes. 
4. Amino Acid Standards 
Glycine (gly), lysine (lys), methylarginine (me-R), and tyrosine (tyr) (Sigma, Inc., 
St. Louis, MO) were individually dissolved in methanol (me-R), (1:1, v:v) 
methanol:water (gly, lys, and phe) and pH 2 water (tyr). Aliquots from these solutions 
were combined and dried under nitrogen at 55°C then derivatized as described above to 
produce solutions containing 50, 100,200, and 300 ng/µL of each amino acid. One µL 
of each of these combined standards was injected and analyzed using capillary GC/MS 
as described above. The peak areas from the chromatographs were utilized to produce a 
calibration curve for each amino acid, which was used to quantitate the amount of these 
amino acids present in the MBP samples from the mutant and control animals. 
RESULTS 
1. Calibration Curves for Amino Acid Standards 
The calibration curves for the four amino acid standards (glycine, lysine, 
methylarginine, and tyrosine) are all roughly linear over the concentration ranges tested 
(50 ng to 300 ng injected) (Figure Vill-1). Extrapolation from the curves for each of 
the standards allows for quantitation of the standards in the samples (Table Vlli-2). 
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2. Amino Acid Analysis of Chromatographs 
of Mutant and Non-Mutant Mice 
The total ion chromatograph of the derivatized hydrolysate of the control mice 
shows a methylarginine peak area of 3,523,593 which corresponds to approximately 
100 ng of methylarginine. The total ion chromatograph of psrt mutant brains does not 
have a methylarginine peak, indicating that the level of Me-R present is below the 
detection limit (Table VIII-2). 
The chromatographs of the derivatized MBP hydrolysate from the psrt mutant 
animals and the non-mutant controls are similar, with many peaks in common. They 
are not, however, exactly alike. The peaks on the chromatograph from the mutants tend 
to be smaller than those from the controls, and there are peaks from the control 
chromatograph that are missing in the mutants. The Me-R peak is clearly seen in the 
control chromatograph, but is missing in the psrt chromatograph (Figures VIII-3 and 
VIII-4). 
DISCUSSION 
The GC/MS analysis indicates that there are no detectable levels of Me-R 
present in the MBP of the pooled psrt mutant brains. This could be due to several 
different reasons. Although the same number of brains were pooled for the psrt and 
control samples, the psrt brains are smaller; therefore, the total mass of mutant brains is 
20.3% less (2.08 grams) than the total mass of the control brains (2.61 grams). In 
addition, the psrt mutants are runted and appear to be developmentally delayed. Even 
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though MBP mRNA and protein expression have been occurring since before day eight 
in normal mice, it is possible that there is a delay in this process in the mutants, which 
would mean that not as much MBP and, therefore, Me-R is present in the mutants as is 
present in age-matched controls. The quantity of material present in the mutant MBP 
hydrolysate as compared to the control MBP hydrolysate (as determined by comparing 
peak areas of tyrosine and lysine to the calibration curves) tends to support this notion 
{Table VII-2). The fact that there was a visible film on the flasks at the end of the MBP 
isolation and the presence of quantifiable amounts of amino acids in the mutant 
chromatographs, however, implies that protein was indeed present. This assay is 
designed to isolate relatively pure MBP and the pH is adjusted to below two in order to 
insure that other basic proteins, such as histones, will precipitate out of solution, leaving 
only the MBP in the final acidic aqueous phase (Maatta et al., 1997). Therefore, MBP 
appears to be present in the mutant brains, even though Me-R was not detected. 
This evidence suggests that a defect in protein arginine methylation is present in 
the mutants; however, it is not conclusive. There was less MBP present in the mutants 
than in the control brains, and the quantity of Me-R detected in the control brains was 
nearing the detection limit for the method. Since multiple brains are required for this 
assay and only a few mutant brains were available for analysis, a single trial was 
conducted using only one of the two mutant strains (1060SJ). A more complete 
analysis involving multiple samples from both mutant strains is needed to conclusively 
determine if the biochemical defect inpsrt mutants affects the methylation of the R-107 
residue of MBP. 
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CHAPTER IX 
EVALUATION OF CANDIDATE GENES 
INTRODUCTION 
A positional cloning strategy, consisting of physical mappmg followed by 
shotgun sequencing of genomic clones, was employed to identify two genes (Tip30/Cc3 
and Prmt3) mapping into the same p-region deletion interval as the psrt phenotype. In 
addition, a positional candidate strategy was used to identify a third gene, Glyt2, 
mappmg into the homologous region of the human genome. What follows 1s a 
discussion of each of the three genes and an assessment of their candidacy. 
DISCUSSION 
1. Assessment of the Candidacy of Tip30/Cc3 
The Tip30/Cc3 gene was identified as a candidate gene because it maps into the 
same p-region deletion interval as the psrt phenotype. It was discovered through 
sequence analysis of a BAC clone that is part of the physical map of the region. Since 
Tip30/Cc3 is involved in transcription, a mutation in this gene would affect the 
transcriptional machinery and/or processes in the mutant animals. A ubiquitously 
expressed, transcription-related gene such as Tip30/Cc3 might be responsible for a 
runting phenotype, especially since Cc3 is involved in promoting apoptosis; however, 
Tip30/Cc3 has not been linked to neurological function. 
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The entire coding sequence of the Tip30/Cc3 cDNA was sequenced in the 
control (BJR) and both mutant strains, and no mutations were found. Based on this 
information and the inability to link the function of the Tip30/Cc3 gene product to a 
neurological phenotype, it is not considered a strong/viable candidate for the psrt 
phenotype. 
2. Assessment of the Candidacy of GlyT2 
The human genome sequencing databases were searched for candidate genes mapping 
within 1 lp14-p15, the region homologous to the psrt region ofMmu 7. The aim was to 
find genes associated with phenotypes similar to psrt, namely runting, seizures, and 
prenatal or juvenile lethality. Although no known human disease genes were found to 
map within the interval, the glycine transporter type 2 (GLYT2) gene was identified as a 
candidate because of its involvement in neurological function. 
There are several reasons why Glyt2 could be the gene responsible for the psrt 
phenotype. A mutation in Glyt2 could alter glycine transport in the mutant animals, 
which would lead to nervous system dysfunction and neural degeneration. The 
dysregulation of neurotransmitter transport alters the amount of neurotransmitter 
present in the cell, in both the cytoplasm and in the synaptic vesicles. This has been 
shown to alter synaptic strength (Liu and Edwards, 1997; Pothos et al., 2000). 
Neurotransmitter toxicity, resulting from the accumulation of neurotransmitter in the 
cell, can lead to neuropathological conditions. Dopamine toxicity, for example, has 
been associated with Parkinson's disease (Liu and Edwards, 1997), and elevated 
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extracellular concentrations of glutamate have been associated with a number of 
neurodegenerative diseases, including ALS (Lou Gehrig's disease), Huntington's 
disease, and Alzheimer's disease (Gegelashvili and Schousboe, 1997). 
The seizure phenotype seen in psrt animals is compatible with a loss of 
inhibitory neurotransmission. Their limbs are stiff and extended for the duration of the 
seizure, not unlike the effects of strychnine poisoning, which causes convulsions and 
muscle contractions and is often fatal (Alberts et al., 1996). Strychnine is a glycine 
antagonist, meaning that it competes with glycine at the glycinergic synapses and 
interferes with inhibitory neurotransmission. If the psrt phenotype were caused by 
mutations in Glyt2, then glycine transport would be dysfunctional. Altered glycine 
transport would cause the accumulation of glycine at the postsynaptic membrane, which 
could have a neurotoxic effect on the nervous system and lead to the death of the 
animal. The affect of the accumulation of glycine at the postsynaptic membrane is 
unknown; however, it is likely that excess glycine would cause an increase in inhibitory 
neurotransmission, which is the opposite effect to the observed phenotype. 
In the mouse, CNS and PNS myelination occur after birth (Raine, 1984a). The 
onset of seizures in the psrt mutants occurs between seven and ten days of age, just as 
the nervous systems are developing. Glycinergic motoneurons are associated with 
rhythmic movements, such as locomotion and respiration. These movements involve 
repeating cycles of precisely coordinated excitation and inhibition (Rekling et al., 
2000). Therefore, if glycine transport were dysfunctional in the psrt mutants, there 
would be an effect on rhythmic movements, and the visible effects might increase as the 
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nervous system matures and rhythmic movements increase. This appears to be the case 
with psrt mutants, since the onset of seizure activity occurs at about seven to ten days 
after birth. 
The psrt phenotype could be caused by a mutation in Glyt2. Such a mutation 
would affect glycine transport, and altered glycine transport would severely affect 
nervous system function. The seizures in the psrt mutants are first observed during the 
time that the nervous systems are developing, and death occurs within a week of the 
onset of seizures. Therefore, there is a temporal correlation between the observed psrt 
seizure phenotype and the function of the Glyt2 protein. Since Glyt2 was discovered 
near the end of this project when the molecular work was nearly complete, no molecular 
data are available for it. Molecular expression data are necessary to thoroughly evaluate 
the candidacy of glyt2; without them, no conclusions can be drawn for the candidacy of 
g/yt2. Therefore, although glyt2 appears to be a viable candidate for the psrt phenotype, 
a full assessment of its candidacy must, by necessity, await molecular expression data 
and sequencing. 
3. Assessment of the Candidacy of Prmt3 
In order to assess the candidacy of Prmt3 as the gene responsible for the psrt 
phenotype, it is necessary to examine the link between protein arginine methylation and 
neurological function. The only molecularly characterized mammalian mutation 
involving a protein arginine methyltransferase gene involves the mouse Prmtl gene. 
Unfortunately, Prmtl null homozygotes die at around day E6.5; therefore, it is 
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impossible to determine the effect(s) of Prmtl on the developing nervous system. 
There is, however, one other well-known link between protein arginine methylation and 
nervous system function, and it involves the myelin basic protein (MBP). 
Myelin is a membrane architecture found within the central (CNS) and 
peripheral (PNS) nervous systems. Its function is to insulate the axon, thereby 
increasing the velocity of the nerve impulse (Kim et al., 1997b; Raine, 1984a; Alberts et 
al., 1996). Myelin contains about 80% lipid and 20% protein, and MBP comprises 
approximately 30% of the total CNS protein (Lees and Brostoff, 1984). 
MBP is a peripheral membrane protein localized to the major dense line regions 
of compact CNS and PNS myelin. It is located on the cytoplasmic side of the 
phospholipid bilayer of either the oligodendrocyte in the CNS or the Schwann cell in 
the PNS (Raine, 1984a). During CNS development, certain hnRNPs bind to and 
transport MBP mRNA from the nucleus to the distal ends of the oligodendrocyte 
processes. Once there, the MBP mRNA is anchored to the myelin membrane and 
translated into protein (Hoek et al., 1998). As myelinogenesis progresses, the 
cytoplasm is extruded and the membranes begin to wrap spirally until multiple layers of 
membrane and protein surround each axon (Omlin et al., 1982; Raine, 1984a). A 
similar process occurs in the Schwann cell in the PNS, except that MBP comprises a 
smaller percentage of the total protein in PNS myelin (Lees and Brostoff, 1984; Raine, 
1984a). 
MBP undergoes several posttranslational modifications; however, the 
methylation of the arginine-107 (R-107) residue appears to be a nearly universal 
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modification. Only one exception, carp, has ever been noted (Kies et al., 1972; Deibler 
and Martenson, 1973; Young et al., 1987). The methylation of the R-107 residue is 
critical to the function of MBP within the myelin membrane, affecting the ability of the 
protein to bind to the myelin membrane. This methylation is also involved in 
maintaining the integrity of the myelin sheath (Kim et al., 1997b; Zand et al., 1998; 
Boggs et al., 1999), and has been implicated in multiple sclerosis (MS), possibly as the 
autoantigen responsible for the disease (Moscarello et al., 1994). Irrespective of the 
cause of the disease, however, the MBP from MS patients contains less methylarginine 
than would be expected (Moscarello et al., 1994; Rawal et al., 1995a; Kim et al., 
1997b ). Therefore, there appears to be a correlation between MBP methylation and the 
demyelination that occurs in MS, which supports the assertion that a defect in MBP 
methylation could be responsible for the neurological phenotype seen in psrt mutants. 
There are at least eight known hereditary diseases that cause a dysmyelination 
phenotype m humans (metachromatic leukodystrophy, Krabbe's disease, 
adrenoleukodystrophy, Refsum's disease, Pelizaeus-Merzbacher disease, Alexander's 
disease, Canavan's disease, and phenylketonurea). However, none of these diseases is 
known to directly involve MBP (Raine, 1984b ). In the mouse, there are several well-
characterized mutants with a dysmyelination phenotype. These include jimpy (jp), 
quaking (qk), murine muscular dystrophy (dy), Trembler (Tr), shiverer (shi) and myelin 
deficient (shim1d) (Raine, 1984b ). Although MBP levels are lowered in some of these 
mutants (Bourre et al., 1980; Jacque et al., 1983), only two of them, shi and shimld have 
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been shown to be mutations in the MBP gene itself (Roach et al., 1983; Popko et al., 
1987). 
The shiverer (shi) mutation is an autosomal recessive mutation that maps to 
Mmu 18 (Barbarese et al., 1983; Sidman et al., 1985; Raine, 1984b). It is a lethal 
mutation, characterized by seizures, with death occurring between two and five months 
of age (Readhead et al., 1987). Shiverer mice exhibit severe dysmyelination. The CNS 
in these mice is characterized by grossly disorganized myelin sheaths (Rosenbluth, 
1980a); however, only subtle changes are detectable in the PNS myelin (Kirschner and 
Ganser, 1980; Rosenbluth, 1980b ). Brains of shi mice contain virtually no MBP mRNA 
or protein (Roach et al., 1983). The myelin deficient (shimld) mutation is allelic to shi, 
with shimld animals exhibiting a similar, but less severe phenotype. The CNS of shimld 
mice is hypomyelinated, and death occurs at a later time, between five and nine months 
of age. Unlike shi mice, however, shr 1d homozygotes express reduced, but detectable, 
levels of MBP mRNA and protein (Popko et al., 1987). Molecular analysis indicates 
that the shi mutation involves a nearly complete deletion of the MBP gene (Roach et al., 
1983). The shimtd mutation, on the other hand, stems from the presence of multiple, 
linked copies of the MBP gene, with some of these copies containing a rearrangement, 
but at least one intact MBP gene (Popko et al., 1987). 
If the function of the PRMT3 protein is to methylate the R-107 residue ofMBP, 
then it becomes necessary to address the question of why the phenotype of psrt animals 
is so much more severe than the phenotypes of either shi or shimtd mice. Since the shi 
allele is a deletion of MBP and the shi phenotype is characterized by the near absence of 
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MBP, shi is considered to be a null mutation; yet the animals live between two and five 
months. The shimtd mutation is hypomorphic, with very low levels of MBP detected in 
the mutants, and these animals live between five and nine months. Conversely, psrt 
animals, which presumably have a wild-type MBP gene but may lack the ability to 
properly methylate the MBP protein, live only 15 to 18 days after birth. 
Although this evidence appears at first to be to the contrary, it does not preclude 
the possibility that the function of the PRMT3 protein is to methylate the MBP. The shi 
mutation is carried on a Swiss Vancouver (SWV) background (Bird et al., 1978; Hogan 
and Greenfield, 1984), while psrt is on a BJR background. The genetic background of 
the shi animals is different from the psrt animals, and it has been shown that genetic 
background can have a dramatic effect on phenotype. For instance, mice homozygous 
for a transgenically inserted null allele of the epidermal growth factor receptor (Efgr) 
display a variety of phenotypes, depending on the genetic background of the transgenic 
animal. These phenotypes are all lethal; however, death can occur anytime from peri-
implantation (on a CF-1 background) to mid gestation (on a 129/Sv background) to 20 
days after birth (on a 129/Sv x C57BL/6 x MFl background) (Sibilia and Wagner, 
1995; Threadgill et al., 1995). Therefore, mutations affecting the same biochemical 
processes (i.e. myelination) in different strains of mice (i.e. SWV and BJR) can have 
widely differing phenotypes due to the differences in genetic background. 
Since the psrt phenotype includes runting in addition to the neurological 
(seizure) phenotype, it is also possible that PRMT3 may have more than one in vivo 
substrate and, consequently, a mutation in Prmt3 could cause more than one effect. 
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This idea of multiple substrates is supported by the fact that the MBP gene is expressed 
only in the nervous system, in oligodendrocytes and Schwann cells (Raine, 1984a), 
while Prmt3 is ubiquitously expressed. Therefore, the differences in phenotype 
between psrt and shi animals could be caused by either one or both of two things: ( 1) 
the mutations are on different genetic backgrounds, and (2) there is more than one 
substrate for PRMT3, which could amplify the pheyotypic effect of a mutation in the 
gene. 
PRMT3, unlike other known PRMTs, contains a zinc-finger motif, and it has 
been suggested that this specific part of the protein is responsible, at least in part, for its 
substrate specificity (Frankel and Clarke, 2000). Zinc fingers are associated with ligand 
binding, most commonly with protein-DNA binding, but also with protein-RNA and 
protein-protein interactions (Mackay and Crossley, 1998). Since the MBP mRNA is 
bound to an hnRNP, it seems reasonable that the enzyme responsible for methylating 
the MBP might be capable of binding either to the MBP mRNA, the hnRNP that carries 
it to its final destination, or the MBP itself. Furthermore, immunolocalization studies 
indicate that PRMT3 is primarily cytoplasmic (Tang et al., 1998). Once transcription is 
complete (in the nucleus), the nascent MBP mRNA binds to an hnRNP and is 
transported from the nucleus to the end of the oligodendrocyte process, where it is 
anchored to the membrane and translated into protein (Hoek et al., 1998). It is 
reasonable to expect that any protein responsible for modifying MBP would be 
localized in the cytoplasm, since the MBP mRNA spends most of its lifetime in the 
cytoplasm and the MBP protein is entirely cytosolic. Therefore, the ligand-binding 
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capabilities and the intracellular location of the PRMT3 protein are consistent with 
those of an enzyme that could modify MBP. 
Earlier studies have suggested that a single methyltransferase could be 
responsible for all three types of methylarginine; however, it was later determined that 
the Type I activity (producing Me2Arg and Me2(asym)Arg) and the Type II activity 
(producing Me2Arg and Me2(sym)Arg) could be separated (Lee et al., 1977). Despite 
the isolation of specific methyltransferase activities and numerous efforts to purify the 
proteins responsible, all attempts to purify to homogeneity and sequence the proteins 
responsible for these activities have failed (Lin et al., 1996; Gary and Clarke, 1998; 
Tang et al., 2000). It is interesting to note that the enzyme responsible for the Type I 
activity (producing solely MeArg and Me2(asym)Arg) is inhibited by MBP, a substrate 
for the Type II activity (Park et al., 1989). Competitive inhibition of an enzyme by its 
product is a common phenomenon; however, MBP from mature myelin contains only 
MeArg and Me2(sym)Arg, making it a product of the Type II, and not the Type I PRMT 
enzyme. This suggests that the criteria for classifying PRMT enzymes may not be 
absolute, and that MBP could be methylated by an enzyme that has been classified as 
Type I. 
Although a GST-PRMT3 fusion protein has been shown to exhibit Type I 
PRMT activity, meaning that it produces solely MeArg and Me2(asym)Arg residues in 
an artificial substrate (Tang et al., 1998; Zhang et al., 2000), there is evidence 
suggesting that native PRMTs and their GST fusion proteins may have different 
properties (Frankel and Clarke, 2000). Since the natural substrate for PRMT3 has not 
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been identified (Smith et al., 1999) and the native protein has not yet been isolated and 
purified, it is impossible to know for certain how PRMT3 functions in vivo. Therefore, 
it is possible that the native PRMT3 protein, unlike the fusion protein containing only a 
part of the total enzyme, might exhibit some Type II PRMT activity in vivo. 
Along these same lines, it has been assumed that the PRMT enzyme {Type I or 
Type II) is solely responsible for determining the methylation state of its substrate. 
There is evidence, however, to suggest that the context of, or the environment 
surrounding, an arginine residue can also affect its methylation state (Rawal et al., 
1995a; Brahms et al., 2000). In order for Sm proteins Dl and D3 to be properly 
(symmetrically) dimethylated, they must first be assembled into their native hetero-
oligomeric complex. Unassembled Dl subunits are improperly (asymmetrically) 
dimethylated (Brahms et al., 2000). It has also been shown that immature myelin 
contains a higher abundance of exon-2-containing MBP isoforms (Kruger et al., 1999). 
These proteins would vary in their N-terminal residues, which are a part of the NAR (N-
terminal acidic region) containing the methylated R-107 residue. Since the methylation 
status of MBP changes as the myelin matures (Rawal et al., 1995a), it is possible that 
the change in the environment near the R-107 residue is affecting the methylation status 
of R-107. Furthermore, it has been shown that MBP undergoes a steric transformation 
upon binding to lipids, with an increase in secondary structure of the protein (Lees and 
Brostoff, 1984). A change in environment could result either from the presence of 
different MBP isoforms at different developmental stages or through steric changes in 
the protein resulting from the association of MBP with other proteins or membrane 
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lipids. This opens the possibility that the enzyme responsible for modifying the MBP 
might act as a Type I enzyme under certain circumstances but, when the context of the 
R-107 changes, can act as a Type II enzyme. Therefore, despite reports that GST-
PRMT3 exhibits no Type II activity, until the native protein and its substrate can be 
studied in vivo, it is at least a possibility that MBP could be an in vivo substrate of 
native PRMT3. 
Perhaps the most compelling evidence supporting the candidacy of Prmt3 in the 
psrt phenotype is the temporal correlation between myelination, PRMT activity, and the 
psrt phenotype. In mice exhibiting the psrt phenotype, the onset of seizures occurs 
approximately 7-10 days after birth, with seizure activity increasing in duration and 
intensity until the animal eventually dies, typically between 15 and 18 days after birth. 
In the mouse, MBP mRNA expression is first detectable by northern blot at around 7 
days (Mathisen et al., 1993; Haas et al., 1995). MBP mRNA expression, MBP protein 
synthesis, MBP-specific methylase activity, and myelination occur synchronously, 
peaking at 16-18 days after birth (Campagnoni et al., 1978; Carson et al., 1983; 
Chanderkar et al., 1986; Rawal et al., 1991). Therefore, the onset of seizure activity in 
the psrt animals correlates with the onset of MBP expression and CNS myelination, and 
death occurs at the peak of myelinogenesis. 
There are several reasons why Prmt3 could be responsible for methylating the 
R-107 residue of MBP, a posttranslational modification that is critical to the function of 
MBP within the myelin membrane. If the PRMT3 protein is responsible for this 
methylation, then a mutation in the Prmt3 gene could cause a lethal neurological 
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phenotype such as psrt. Since the in vivo substrates of PRMT3 are unknown, it is also 
possible that there are other PRMT3 substrates (such as bFGF) that, when improperly 
methylated, could lead to either a runting or a neurological phenotype. 
CONCLUSIONS 
Of the three genes examined in this work, Prmt3 is the leading candidate for the 
cause of the psrt phenotype. The entire coding sequence of the Tip30/Cc3 cDNA was 
sequenced for the control and both mutants, and no mutations were found. Based on 
this information and the inability to link the function of the Tip30/Cc3 gene product to a 
neurological phenotype, it is not considered a strong candidate for the psrt phenotype. 
Although Glyt2 does appear to be a viable candidate for a neurological phenotype, it 
was discovered only recently; therefore, a thorough assessment of its candidacy, 
including a molecular expression analysis, has not been completed. 
The most probable assertion, based on the evidence presented, is that Prmt3 is 
the gene responsible for the psrt phenotype. Protein arginine methylation has been 
linked to neurological function. The methylation of the R-107 residue of MBP is 
critical to the function of MBP within the myelin membrane. It has been shown that 
myelin is severely affected by either the absence of MBP (as in shi mice) or incorrectly 
methylated MBP (as in MS). The cellular localization pattern of the PRMT3 protein is 
the same as MBP. Furthermore, there is a temporal correlation between myelination 
and the psrt phenotype. Therefore, if the PRMT3 protein is responsible for methylating 
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the R-107 residue of MBP, then a mutation in the Prmt3 gene could effect a lethal 
neurological phenotype such as psrt. 
It is important to emphasize that PRMT3 could be responsible for the psrt 
phenotype even if MBP is not an in vivo substrate for the enzyme. Mutations in Prmt3 
would lead to the improper methylation of arginine residue(s) in its substrate(s). Since 
the in vivo substrates of PRMT3 are unknown, it is possible that other substrates (such 
as bFGF) exist that, when improperly methylated, could lead to either a runting or a 
neurological phenotype. 
The molecular evidence presented in this work suggests that the psrt mutants 
have altered Prmt3 alleles. Although sequencing efforts have failed to detect a mutation 
in the coding region of the cDNAs from either of the two homozygous mutants, 
preliminary data from a mutation screen utilizing temperature-gradient capillary 
electrophoresis (TGCE) (SpectruMedix, State College, PA) strongly suggest that a 
mutation is present in the 3' end of the transcript from the 1060SJ allele. In addition, 
MBP from 14 day old 1060SJ mutants contains no detectable amounts of MeArg, while 
MeArg Cc!Jl be easily seen in age-matched littermate controls. This indicates that there 
is a lack ofMBP-specific PRMT activity in the 1060SJ mutants. 
The TGCE data also suggest a mutation in the 3' end of the transcript of the 
723SJ allele, which has been difficult to characterize molecularly. The S'end of the 
723SJ Prmt3 transcript could not be amplified, either by standard RT-PCR or 5' RACE. 
Northern blot analysis indicates that the 723SJ transcript may be shorter than the 
1060SJ allele and the control; however, this difference is only very slight, at best. This 
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suggests that some type of genomic rearrangement or microdeletion may be present in 
the 723SJ allele. Unfortunately, an initial attempt to verify an alteration in the 723SJ 
allele was unsuccessful. 
Molecular and biochemical evidence presented in this work support the assertion 
that the psrt animals have an alteration in the Prmt3 transcript. This evidence, together 
with the nature of the phenotype, leads to the conclusion that the Prmt3 gene is 




The findings from this work suggest that Prmt3 is the gene responsible for the 
psrt phenotype. They do not, however, prove this assertion. In order to prove 
unequivocally that Prmt3 is the gene responsible for the psrt phenotype, there are 
several experiments that need to be done. First of all, the 5' end of the 723SJ Prmt3 
transcript will have to be sequenced. Since RT-PCR and RACE failed to accomplish 
this, it will be necessary to sequence from genomic DNA. Even if another Southern 
blot (using different restriction enzymes) shows a rearrangement or deletion, sequence 
data will be necessary to define the nature of the mutation. It is also important to find 
the mutations that the TGCE heteroduplex analysis indicates are present in the 3' ends 
of the mutant transcripts. Further sequence analysis, utilizing either genomic DNA or 
cDNAs, will be needed. The larger transcripts detected in skeletal muscle and heart 
also must be characterized. 
In order to prove that the biological function of the Prmt3 gene is to methylate 
MBP, an additional Me-R assay must be performed, this time using both mutant strains. 
The experiment should be repeated using more brains ( and, therefore, more MBP) so 
that the level of Me-R detected in the control animals is substantially above the 
detection limits for the procedure. And finally, either a gene knock-out from a wild 
type animal or a transgenic rescue of a mutant will serve as definitive proof that Prmt3 
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Figure 11-1. The Limits of the p-Deletion Complex. Mouse chromosome 7 is 
represented by the central horizontal line, with the centromere to the left and the 
telomere to the right. Molecular markers are listed directly above the chromosome and 
phenotypes that have been mapped but not molecularly characterized are listed directly 
below the chromosome. Ldh3, Myodl, Saal, and ru2 are loci that cannot be ordered 
relative to the centromere. The heavy, shorter horizontal lines below the chromosome 
represent two of the p deletions. p 46DFiOD is the most proximally extending deletion and 
p 30PUb is the most distally extending deletion. Their proximal and distal breakpoints, 
respectively, define the limits of the p-deletion complex. This figure is adapted from 
Dhar MS, Johnson DK (1997) A microsatellite map of the pink-eyed dilution (p) 
deletion complex in mouse Chromosome 7. Mamm Genome 8, 143-145. 
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Figure 11-2. Mutagenesis Scheme Using the p 46DFiOD Deletion to Select New 
Recessive Mutations. The mutagenized chromosome has two morphological markers, 
ru2 and p. The mutagenized Go male animal is crossed to an animal that is homozygous 
wild type at both the p and ru2 loci to produce phenotypically wild-type G1 offspring. 
G1 animals are crossed to animals carrying the p 46DFiOD deletion opposite ru2 (in this 
case). The G2 offspring fall into three classes: wild-type (which represents two 
genotypes), the ru2 carrier class, and the ru2 p test class. This figure is adapted from 
Rinchik EM, Carpenter DA, Handel MA (1995) Pleiotropy in microdeletion syndromes: 
Neurological and spermatogenic abnormalities in mice homozygous for the p 6H deletion 
are likely due to dysfunction of a single gene. Proc Natl Acad Sci USA 92, 6394-6398. 
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Figure 111-1. Mapping the psrt Phenotype by Trans-Complementation Analysis. 
There are four p deletions that fail to complement the psrt phenotype: p 46DFioD, p 47Dm, 
p 2MNURf, and p 3RD3ooH_ All other deletions complement the phenotype. Therefore, the 
psrt minimal region, which is represented by the large gray rectangle, is defined as the 
deletion interval bordered proximally by the proximal breakpoint of p 2MNURJ and 
bordered distally by the proximal breakpoints of p 8RlSOM and p 80 \ which cannot be 
resolved at this time. At the beginning of this project, the endpoints of the p3RD 3ooH 
deletion had not been well characterized, so this deletion is not included in this map. 
Ldh3, Myodl, and Saal are loci that cannot be ordered relative to the centromere. The 
white box on the p 8°K deletion indicates that it is a "skipper," or a noncontiguous 
deletion that is most likely a complex rearrangement. 
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Table IV-1. STSs Used in Physical Mapping. 
NameofSTS Description of STS Method How Used 
D7Mit26 microsatellite PCR BACDNAs 
D7Mit69 microsatellite PCR BACDNAs 
D7Mit70 microsatellite PCR BACDNAs 
D7Mit84 microsatellite PCR BACDNAs 
D7Mitl45 microsatellite PCR BACDNAs 
D7Mit160 microsatellite PCR BACDNAs 
D7Mitl93 microsatellite PCR BACDNAs 
D7Mit229 microsatellite PCR BACDNAs 
D7Mit230 microsatellite PCR BACDNAsand 
deletion panel DNAs 
RT 591/592 RT-PCR product PCRand BAC DNAs and BAC 
(Prmt3) Hybridization Southern blots 
RT 595/596 RT-PCR product Hybridization Deletion panel blots 
(Prmt3) 
B36n 10/EcoRV /SP6 BACend Hybridization BAC Southern blots 
B36n10/EcoRV/T7 BACend Hybridization BAC Southern blots 
B4514/Pvu/T7 BACend Hybridization Deletion panel blots 
and BAC Southern 
blots 
ORN 609/610 PCR product (same PCR BACDNAs 
as B4514/Pvu/T7) 
B 1 79d 14/EcoRV /SP6 BACend Hybridization Deletion panel blots 
and BAC Southern 
blots 
B 179d 14/EcoRV /T7 BACend Hybridization Deletion panel blots 
and BAC Southern 
blots 
B36n10/B2A Single Primer PCR Hybridization Deletion panel blots 
product 












Figure IV-2. The p-Deletion Complex with New Microsatellite Markers. 
D7Mit230 and D7Mit312, two markers that were mapped as part of this project, are 
included on this map. D7Mit230 maps to the same deletion interval as D7Mit193, and 
D 7 Mit312 maps outside the p-deletion complex. The two most proximally and distally 
extending of the p-deletions, p 46DFiOD and p 30PUb' are shown. This figure is adapted 
from Dhar MS, Johnson DK (1997) A microsatellite map of the pink-eyed dilution (p) 
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Figure IV-3. Defining the Breakpoints of the p 3RDJOOH Deletion. PCR analysis 
indicates that three microsatellite markers map within the p3RD 3ooH deletion: D7Mit193, 
D7Mit230, and D7Mit145. p3RD 3ooH does not delete five other microsatellites that were 
tested: D7Mit26, D7Mit69, D7Mit70, D7Mit84, and D7Mitl 60. These data indicate 
that p 3RDJOOH is a noncontiguous deletion ( or a "skipper") since it does not delete 
D7Mit70. Previous studies indicate that the p 3RDJOOH deletion encompasses three 
molecular markers: p, Gas2, and D7Hl 5F37Sl (Johnson et al., 1995). This places the 
proximal breakpoint of p3RD 3ooH between D7Mit26 and D7Mit69, which cannot be 
resolved at this time, and the distal breakpoint between D7Mit84 and Gabra5. 
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Table IV-4. Physical Mapping Data from BACs. 
BAC D7 D7 D7 D7 D7 RT RT ORN ORN B36n!O/ B36n!O/ B36n!O/ B179dl4 B179dl4/ B207 B211 
Mit Mil Mit Mit Mit 591/ 595I 607/608 609/610 B2A SP6 T7 end BIB pl7/SP6 i3m 
145 /93 /94 229 230 592 596 <Bl79dl4end) '84514ml 
B36nl0 + + + + 
B4514 + + + 
B179dl4 + + + + + + + + + + 
B207017 + + 







B242212 + + + 
B279114 
B288k21 + + 
B315k22 + + 
B329d6 + + + + 
B333e23 + + + 
B34416 + + 
B354kl 1 + 
B372f7 + + 
B382013 + + 
B434210 + + + + + 
B462al5 + + 







Figure IV-5. The Revised psrt Minimal Deletion Interval. The fine-mapping of the 
p 3RD3ooH deletion enables the map of the minimal deletion interval to be revised to 
include the extents of all four p deletions that fail to complement the psrt phenotype: 
46DFiOD 47DTD 2MNUR/ and 3RD300H p ,p ,p ' p . All other deletions that have been tested 
complement the phenotype. Therefore, the psrt minimal region, which is represented 
by the large gray rectangle, is now defined as the deletion interval bordered proximally 
by the proximal breakpoints of both p2MNUR/ and p 3RD300H, which cannot be resolved at 
this time. The region is bordered distally by the proximal breakpoints of p8°K and 
8R250M h" h 1 b 1 d h" . p , w 1c a so cannot e reso ve at t 1s time. 
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Table IV-6. Insert Sizes and Notl Restriction Data for Selected BACs. 
BAC Type of Screened Using Size of Insert Notl 
Library Restriction Sites 
B36n10 PCRpools D7Mit193 120kb 1 
B4514 PCRpools D7Mit193 120kb 1 
B179d14 PCRpools D7Mit193 150 kb 1 
B207p17 PCRpools D7Mit145 280kb 2 
B211i3 PCRpools D7Mit230 125 kb 1 
B212f2 PCRpools D7Mit145 190 kb 0 
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Figure IV-7. Physical Map of the psrt Region of Mouse Chromosome 7. The 
centromere of the chromosome is to the left of the diagram, and the telomere is to the 
right. The relevant p deletions are drawn above the chromosome, with the line 
representing the area deleted. BACs are drawn below the chromosome and are labeled 
with the BAC name and size, if known. The psrt minimal interval is represented by the 
bold vertical lines and is labeled at the bottom of the figure. Molecular markers 
relevant to this study are represented as colored dots. Grey dots are microsatellite 
markers, with light grey representing those that have been previously mapped and dark 
grey representing those mapped as part of this work. Blue dots represent BAC ends, 
yellow dots are STSs generated using single primer PCR, and red dots are expressed 
sequences generated from RT-PCR. This map is not drawn to scale. 
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Figure IV-7: Physical Mapping in the psrt Region of Mouse Chromosome 7 
D7Mit193 Not! Restriction Site 
• 1 . l----.i·►1~-----I .. ◄---►.i◄ Ttp30/Cc3 ►◄ _:_ Prmt3 ► ◄ 
~15 kb ~85 kb 
~5 kb ~25 kb ~20kb 
Figure V-1. Structure of the Insert of BAC Bl 79dl4. The Tip30/Cc3 and Prmt3 
genes are transcribed in the same direction. The Notl restriction site is in the CpG 
island near the 5' end of Prmt3, and D7Mit193 is near the 5' end of Tip30/Cc3. The 
length of the BAC insert is approximately 150 kb. 
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Table V-2. Exon and Intron Sizes for Tip30/Cc3. 











Table V-3. Exon and Intron Sizes for Prmt3. 
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Table VII-1. Primers Used for Standard PCR, RT-PCR and RACE. 
Primer Primer Sequence (5' - 3') Gene Corresponding 
Name b ofcDNA 
ORN644 Prmt3 554-573 
ORN645 Prmt3 712-693 
ORN646 Prmt3 1166-1185 
ORN 647 Prmt3 1238-1219 
ORN648 Prmt3 1751-1735 
ORN663 C Ti 30/Cc3 1-20 
ORN664 Ti 30/Cc3 1059-1039 
ORN704 Prmt3 (-18 - (-6) 
ORN723 Ti 30/Cc3 305-323 
ORN726 Ti 30/Cc3 323-305 
ORN727 Ti 30/Cc3 596-614 
ORN728 Ti 30/Cc3 614-596 
ORN 772 632-609 
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Prmt3 cDNA 
-18 -6 554 573 693 712 1166 1185 -1219 1238 1735 1751 
I I I I I I I I I I I I 
ORN 645/704 (569 hp) ORN 646/648 (586 bp) 
ORN 704/722 (463 bp) ORN 646/677 (424 bp) 
ORN 645/719 (283 bp) ORN 648/676 (251 bp) 
ORN 644/647 (685 hp) 
ORN 644/660 (204 bp) 
ORN 647/661 (530 bp) 
Figure VII-2. Prmt3 cDNA Fragments Used for Heteroduplex Analysis. The Prmt3 
cDNA is represented by the long horizontal line at the top of the figure, and the 
numbers refer to the nucleotides corresponding to some of the PCR primers. (The start 
codon is at position 1.) The shorter, horizontal lines in lighter print are the smaller RT-
PCR amplification fragments analyzed using TGCE. These fragments range in size 
from 204 bp to 530 bp. The darker horizontal lines below the cDNA are the original 
RT-PCR fragments used for sequence analysis, which range in size from 569 to 685 bp. 
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Figure VII-3. RT-PCR Analysis of the Tip30/Cc3 cDNA. (a) The cDNA is 
represented by the numbered horizontal line near the top of the figure, numbered so that 
hp 1 is the first nucleotide of the start codon. Three sets of primers, represented by the 
numbered arrows, were used to amplify overlapping fragments for sequence analysis. 
The horizontal lines at the bottom of the figure represent the amplification fragments. 
(b) RT-PCR amplification products run on ethidium bromide-stained agarose gels. A 
single primer pair (ORN 663/664) was used to amplify a 1060 hp fragment representing 
the entire Tip30/Cc3 coding sequence for expression analysis. The mutants and 
controls show no size difference. A 520 hp amplification fragment from (3-actin, 




I I ... 
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305 323 
I I ... 
723 
ORN 663/728 ( 615 bp) 
596 614 











ORN 664/727 (464 bp) 
ORN 723/726 (560 bp) 
ORN 663/664 (1060 bp) 
(b) 
723SJ 1060SJ BJR 
+ - + - + -
._ ORN 663/664 
(1060 bp) 
'3-actin 
._ ORN 559/560 
(586 bp) 
Figure VII-3. RT-PCR Analysis of the Tip30/Cc3 cDNA. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 
1 = heart 
2 = brain 
3 = spleen 
4 = lung 
5 = liver 
6 = skeletal muscle 
7 = kidney 





9 = 7-day embryo 
10 = 11-day embryo 
11 = 15-day embryo 
12 = 1 7-day embryo 
13 =(-)control 
Figure VII-4. Tip30/Cc3 Multiple Tissue Expression Analysis. Primers ORN 
663/664 were used with cDNAs from the mouse multiple tissue panel to amplify a 1060 
hp fragment of the Tip30/Cc3 cDNA containing the entire coding sequence. A single 
band of the expected length was detected in all tissues analyzed. A 520 hp fragment 
from {3-actin, amplified using primers ORN 559/560, was the control. 
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Figure VII-5. RT-PCR Analysis of the Prmt3 cDNA. (a) The cDNA is represented 
by the numbered horizontal line near the top of the figure, numbered so that bp 1 is the 
first nucleotide of the start codon. Three sets of primers, represented by the numbered 
arrows, were used to amplify overlapping fragments for sequence analysis. The 
horizontal lines at the bottom of the figure represent the amplification fragments. (b) 
RT-PCR amplification products run on ethidium bromide-stained agarose gels. The 
mutants and controls show no size difference in the bands; however, the 723SJ cDNA 
produces no amplification product with the ORN 645/704 primers. A 520 bp 
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(b) 
723SJ 1060SJ BJR 
+ - + + - ..._ ORN 645/704 
(569 hp) 
..._ ORN 644/647 
(685 hp) 





Figure VII-5. RT-PCRAnalysis ofthePrmt3 cDNA. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 - : --....- - ..... - - . -- - - ............ 
1 = heart 
2 = brain 
3 = spleen 
4 = lung 
5 = liver 
6 = skeletal muscle 
7 = kidney 
8 = testis 
9 = 7-day embryo 
10 = 11-day embryo 
11 = 15-day embryo 
12 = 17-day embryo 
13 =(-)control 




Figure VII-6. Prmt3 Multiple Tissue Expression Analysis. Primers ORN 646/648 
were used with cDNAs from the mouse multiple tissue panel to amplify a 586 bp 
fragment from the 3' end of the Prmt3 cDNA. A band of the expected length was seen 
is all tissues analyzed, and a second, larger band is seen in skeletal muscle and possibly 
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Figure VII-7. Northern Blot of Mutant and Control Brains Probed with a Prmt3 
Probe. This blot contains total RNAs from the brains of psrt mutants (m) and non-
mutant littermate controls (c) from both the 723SJ (genotype ru2 ++I Df [ru2-p]) and 
1060SJ (genotype++ p I Df[ru2-p]) mutant stocks. Df[ru2-p] represents the p46DFiOD 
deletion. The blot was probed with a RT-PCR fragment representing the 5' end of the 
Prmt3 cDNA (ORN 645/704). The 723SJ mutant transcript appears to be slightly 
shorter than the other transcripts. 
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Table VII-8. Restriction Data for DNA Used in the Genomic Southern Blot 
(Figure VII-9). 
Enzyme # restriction sites Smallest fragment Largest fragment 
BstXI 13 39 4966 
EcoRI 5 3287 5979 
Pstl 20 29 3735 
Taql 9 992 5258 
These data represent 25-kb of genomic DNA, from 5-kb upstream of the start codon of 
Prmt3 to 20-kb downstream. 
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Enzyme: Pstl Taql 
a b c 
EcoRI 








a = 723SJ psrt homozygote 
b = BJR control 
c = 1060SJ psrt homozygote 
BstXI. 
a b 
Figure VII-9. Autoradiograph from a Genomic Southern Blot of psrt mutants. 
The blot was probed with 5' end of the prmt3 cDNA. Listed above the photograph are 
the enzymes used for digestion and a representation for the genomic DNA present in 
each lane. To the left of the photograph are arrows corresponding to the size markers 
from the 1-kb plus DNA ladder (not shown). The legend for the DNAs is below the 




Figure VII-10. Electropherograms from the TGCE Analysis of the psrt Mutants. 
(a) The RT 646/677 fragment from the BJR control and the (b) 723SJ psrt homozygote 
mixed with the BJR control. There is a single large peak in electropherogram (a) and 
two smaller peaks to the right of the main peak in (b). (c) The RT 648/676 fragment 
from the BJR control and the ( d) 1060SJ psrt homozygote. There is a single large peak 
in electropherogram ( c) and a smaller peak that appears as a distinct "shoulder" to the 
right of the main peak in (b ). The multiple peaks present in both (b) and ( d) indicate a 
mismatch between the control and mutant cDNAs. 
180 
Prmt3cDNA 
bp 1166 1501 1590 1751 
II 
II I I I I 
ORN 646/648 (586 bp) ;-: -------;,-------.----------
3' end of Prmt3 cDNA !,',,,,, i 723SJ . 
: ~utatio~ ! 
ORN 646/677 (424 bp) i ; ; 
ORN 648/676 (251 bp) I :◄ 
1060SJ 
mutation 
Figure VII-11. Prmt3 RT-PCR Fragments Containing Mismatches. Mismatches 
were detected in both the ORN 646/677 and the ORN 648/676 fragments for the 723SJ 
strain, indicating that the mut~tion is most likely in the 89 bp of sequence that overlaps 
in those two fragments. A mismatch was detected only in the ORN 648/676 fragment 
in the 1060SJ strain, indicating that the mutation is most likely in the 162 bp of 
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Figure VIII-1. Calibration Curves for Amino Acid Standards. The concentration 
of these four amino acids in a sample can be determined by extrapolation if the 
corresponding peak area is known. 
Table VIII-2. Extrapolated Quantitation Data. 
Sample 
Lysine Peak Lysine Me-R Peak Me-R Tyrosine Tyrosine 
Area Quantity Area Quantity Peak Area Quantity 
psrt 
41,414,848 ~lOOng NIA NIA 13,242,394 ~25 ng 
mutantsa 
non-psrt 
87,584,333 ~200ng 3,523,593 ~100 ng 57,284,175 ~75 ng b controls 
a The pooled mutant sample class included five homozygotes (genotype ru2 mp I ru2 mp) and 
two hemizygotes (genotype ru2 mp I D}Iru2-p]) 
b The pooled control sample class included five wild-type animals (genotype ru2 + + I + + p) 














Figure VIII-3. Total Ion Chromatographs of MBP Hydrolysate from Control and 
Mutant Animals. Chromatographs from age-matched (a) 1060S1 control animals, and 
(b) 1060SJ psrt mutant animals. The genotypes of these animals are noted in Table 
Vill-2. The circled regions represent the area surrounding the Me-R peak, which is 
identified by its retention time and its mass spectrum. This peak is missing in the 
chromatograph from the mutant animal. An expanded view of the circled regions can 
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Figure VIII-4. Expanded View of the Me-R Region of the Total Ion 
Chromatographs of MBP Hydrolysate from Control and Mutant Animals. 
Chromatographs from age-matched (a) 1060SJ control animals, and (b) 1060SJ psrt 
mutant animals. The genotypes of these animals are noted in Table VIII-2. The circled 
regions represent the Me-R peak, which was identified by its retention time and its mass 
spectrum. This peak is not present in the chromatograph from the mutant animal. 
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